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… Op basis van een deelverzameling van metingen kun je een logische consistente 
geschiedenis definiëren, waarvan je echter niet kunt zeggen dat die waar is; ze kan 
staande gehouden worden zonder tegenstrijdigheden… 
 
(Elementaire deeltjes, M. Houellebecq) 
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CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
Technical mixtures of polychlorinated biphenyls (PCBs) were widely used 
industrial chemicals due to their chemical stability, their thermal conductivity, their 
miscibility with organic solvents (i.e. lipophilicity), and their dielectric properties (Fig. 
1A). By leakage from industrial devices, careless disposal practices, and accidents, 
PCBs were introduced into the environment where they persisted due to their 
chemical stability and their lipophilicity. 
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Figure 1. The general chemical structure of a polychlorinated biphenyl (A) and 
tetrachlorobenzyltoluene (B). The 4 or 4’ positions are also known as para, the 3, 3’, 5, and 5’ 
positions as meta and the 2, 2’, 6, or 6’ positions as ortho. 
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These characteristics cause that PCBs accumulate in higher trophic levels of the 
food chain (Safe, 1994) and induce toxic effects like, acute lethality, hepatomegaly, 
fatty liver, porphyria, body weight loss, dermal toxicity, thymic atrophy, 
immunosuppressive effects, reproductive and developmental toxicity (Safe, 1994). 
Hence, international regulations restricted the use of PCBs during the 1970s. These 
regulations induced the development of alternatives for PCBs. Ugilec 141 (Fig. 1B) is 
one of these PCB substitutes. This chemical mixture, consisting of 69 different 
isomers (Ehmann and Ballschmiter, 1989), shares similar physicochemical properties 
with PCBs, like the lipophilicity (Kow) and the water solubility (VanHaelst, 1996); 
Leonards and DeVoogt, 1989).  
Ugilec 141 has been used as a hydraulic fluid in the mining industry in Germany 
since the early 1980s at approximately 1500 tons a year (Poppe et al., 1988). Leakage 
from these hydraulic devices introduced TCBTs into the environment. In the rivers 
near and down stream the mines, levels of TCBTs between 0.1 and 25 mg. kg-1 tissue 
were found in fish (Friege et al., 1989; Fuerst et al., 1987a; Poppe et al., 1988; 
Roennefahrt, 1987; Wammes et al., 1997), which were comparable to PCB levels 
(Leonards and DeVoogt, 1989; Wammes et al., 1997). Thus, TCBTs accumulated in 
fish like PCBs. Additionally, in mice Ugilec 141 appeared to induce biochemical 
changes similar to those induced by Aroclor 1254 but less pronounced. These 
changes included induction of cytochrome P450 1A1 enzyme activity and a decrease 
of plasma thyroxine levels (Murk et al., 1991). In the rat the total amount of 
cytochrome P450 and CYP2B1 activity were marginally induced (VonMeyerinck et al., 
1990). Only a few studies have been performed to determine the tissue distribution 
and accumulation of Ugilec 141 in rats and in fish. Compared to PCBs the 
elimination of Ugilec 141 was faster and consequently, the accumulation was less 
pronounced for TCBTs (Bouraly and Millischer, 1989; VanHaelst et al., 1996a; 
VanHaelst et al., 1996b). Due to similarities with PCBs with respect to their chemical 
characteristics and environmental behaviour, the use of Ugilec 141 in new machinery 
was prohibited in the European Union in 1994. However, Ugilec 141 can still leak 
into the environment from old devices and pose possible health risks. 
The most toxic PCBs induce their dioxin-like toxicity via interaction with the Ah-
receptor (Safe, 1994). They have a planar conformation, which is an important 
requirement to interact with the receptor. One study has been performed to estimate, 
which TCBTs could adopt a coplanar conformation and could possibly interact with 
the Ah-receptor. Semi-empirical molecular modelling calculations of ring rotational 
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energy barriers were performed on the possible TCBT isomers (VanHaelst et al., 
1997). Comparing the energy barriers with PCBs resulted in only two (3,3’4,4’-Cl4-
2methyl- and 3,3’,4,4’-Cl4-5-methyl-chlorobenzyltoluene) TCBTs that could interact 
with the receptor and would induce dioxin-like toxicity.  
KINETICS 
The severity of toxic effects induced by xenobiotics depends on the 
concentration of the chemical at the site where the toxic effect occurs, i.e. the target 
site. Thus, insight in the relation between this internal concentration and the effect is 
required to determine at which concentration no detrimental effects occur. However, 
the concentration at the target site is the resultant of many factors like dose, 
physicochemical properties of the chemical and kinetics, i.e. processes that include 
absorption, distribution, metabolism and elimination.  
Absorption and distribution 
Absorption processes include uptake from the gastro-intestinal tract (G.I-tract) 
after oral ingestion, dermal uptake by exposure via the skin and uptake from the lung 
by inhalation. After absorption, the xenobiotics are transported by blood to remote 
tissue and organs, where they could deposit. This depends on the intrinsic properties 
of the tissues and the compound specific characteristics. Many xenobiotics that are 
absorbed from the GI-tract are transported via the portal vein to the liver where they 
can be metabolised before reaching the systemic circulation. This is called first-pass 
elimination. Numerous lipophilic substances, such as DDT and lipophilic vitamins, 
are transported via the lymph (Charman et al., 1997) to the thoracic duct where the 
lymph mixes with the venous blood. Via this route of uptake the liver as first-pass 
eliminating organ is avoided, which entails a higher systemic concentration, i.e. a 
higher bioavailability (Kwan, 1997) relative to the portal vein uptake route. 
Metabolism 
Metabolism of xenobiotics is generally divided in two phases: phase I and phase 
II metabolism. During phase I metabolism xenobiotics are converted into more polar 
metabolites that can be readily excreted, or be conjugated during phase II 
metabolism. The conjugation is followed by biliary or renal excretion. The major 
enzyme system that is involved in phase I metabolism is Cytochrome P450 (CYP). 
This enzyme system is present in hepatic as well as in extrahepatic tissues (Gonzalez, 
1992). The liver contains of the highest CYP concentrations followed by the 
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intestines and the lungs (De Waziers et al., 1990). Within the cells, CYPs are primarily 
located in the endoplasmic reticulum and consist of many different isoforms with 
different substrate selectivity (Gonzalez, 1992). In addition, many of these enzymes 
are differentially inducible e.g. phenobarbital induces CYP2B enzymes while β-
naphthoflavone induces CYP1A enzymes (Parkinson, 1996). The expression of CYP 
enzymes depends on species, dietary and genetic factors (Clarke, 1998). For example 
in fish, the CYP concentrations in the liver are much lower than in mammalian 
species (Sijm and Opperhuizen, 1989). Within the different species, CYP expression 
depends on the diet and the genetic constitution, which is responsible for inter-
individual dissimilarities in enzyme activity and in metabolic rates between individuals 
of one species. 
Elimination 
Elimination is the process of excretion via urine, bile, feces, exhalation via the 
lungs, transpiration via the skin, and via lactation. In general metabolites are excreted 
via these routes, however, depending on the xenobiotic, excretion of parent 
compound also occurs. Small hydrofilic molecules could be eliminated as parent 
compound via the urine, and larger molecules can be excreted into the feces via the 
bile. Some metabolites like glucuronides can undergo metabolism in the gut by 
microflora, which might result in the reformation of the parent compound. 
Subsequently, this compound could be taken up again and metabolised in the liver. 
This process is called enterohepatic circulation. Enterohepatic circulation increases 
chemical half-lives, i.e. the time necessary to reduce the blood concentration with 50 
%.  
KINETICS OF PCBS 
The kinetics of lipophilic substances like PCBs have been studied to large extent 
as reviewed by Matthews and Dedrick, (1984) and VandenBerg et al. (1994). One of 
the main characteristics with respect to the toxicokinetics of the polyhalogenated 
hydrocarbons is the slow elimination from the organism, resulting in life-time 
exposure to these chlorinated highly lipophilic compounds. During this exposition 
the organisms are prone to possible toxic effects, e.g. developmental and reproductive 
effects (Safe, 1994). 
The fact that PCBs , almost 30 years after the ban on their use, are still being 
detected in biota, including humans (Dewailly et al., 1999; Patterson et al., 1994), 
Introduction 
 5  
clearly illustrates the extended exposure periods. TCBTs are physicochemically 
related to PCBs, with respect to octanol to water partitioning (Log Kow of tetra or 
higher chlorinated PCBs range from 5 to 7 and for the TCBTs from 6.5 to 7.5), 
conformational aspects, and dimensions. Hence, similarities between TCBTs and 
PCBs regarding their toxicokinetics can be anticipated, including a slow elimination 
of TCBTs from the organism and accumulation in the adipose tissue. As a 
consequence, TCBTs may pose similar risks as PCBs or other related 
polyhalogenated hydrocarbons, with respect to the possible accumulation of these 
compounds in the environment and biota. A short overview of kinetics of PCBs is 
presented here. 
Absorption 
Humans are generally exposed to PCBs via ingestion of contaminated food. The 
absorption efficiency from the G.I-tract appears to be inversely related to the degree 
of chlorination. In the rat the absorption efficiency ranges from 66 to 96% (Tanabe et 
al., 1981; Fries et al., 1985) while for human adults it ranges between 27 and 88 % 
(Schlummer et al., 1998). Nursing infants absorb PCBs for more than 90 % (Dahl et 
al., 1995; Korner et al., 1992). The absorption efficiency also depends on the PCB 
concentrations in the blood and the gut tissue. High blood levels reduce the uptake 
which is assumed to be caused by reduced diffusion rates (Rohde et al., 1999; 
Schlummer et al., 1998).  
After absorption from the G.I-tract, most of the PCBs enter the intestinal 
lymphatic drainage sequestered in chylomicrons, and are subsequently transported to 
the thoracic duct where the lymph mixes with the venous blood, as was demonstrated 
in dog and sheep (Busbee et al., 1985; Ziprin et al., 1980). In addition, it was shown 
that di-chlorinated PCBs were taken up via the portal vein (Busbee and Ziprin, 1994).  
Once PCBs have entered the bloodstream, they equilibrate rapidly over 
lipoproteins and albumin in the plasma (Becker and Gamble, 1982; Borlakoglu et al., 
1990c; Busbee et al., 1985; Maliwal and Guthrie, 1982; Matthews et al., 1984; 
Mohammed et al., 1990). These studies suggested that the PCBs are transported to 
remote tissue and organ via non-covalent binding to lipoproteins and albumin.  
In vitro it was demonstrated that lipoproteins and albumin facilitated the uptake 
and the elimination of the PCBs. In addition, the tissue disposition of PCBs 
depended also on the lipid solubility of the congeners (Di Francesco and Bickel, 
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1985; Di Francesco et al., 1988; Guo et al., 1987; Rau and Vodicnik, 1986; Shireman, 
1988). 
Distribution and disposition 
PCBs in the bloodstream are initially distributed to the liver and the muscle, 
which can easily be explained by the fact that the liver is a well-perfused organ and 
the muscle is about the largest tissue in volume relative to the total body composition. 
After this initial uptake the PCBs slowly redistribute to skin and adipose tissue 
because of the high lipid content of these tissues (Matthews and Dedrick, 1984; 
Matthews and Anderson, 1975) and the relatively low perfusion rates of these tissues. 
As a consequence, the adipose tissue and skin reach their maximum levels at later 
time points than e.g. the liver. Many studies have shown that among different 
mammalian species, like rat, mice, dog, and monkey, the major storage tissue for PCB 
congeners is adipose tissue, followed by skin, muscle, liver and blood (Heinrich 
Hirsch et al., 1997; Lutz et al., 1977; Lutz et al., 1984; Matthews and Dedrick, 1984; 
Moir et al., 1996; Morales et al., 1979; Sipes et al., 1982a; Sipes et al., 1982b). 
Congener specific distribution was observed (Lutz et al. 1977; Matthews and 
Anderson, 1975; Nims et al., 1994; Morales et al. 1979), which depended on the degree 
of chlorination, the substitution pattern (Borlakoglu et al., 1991; Nims et al., 1994), 
and the tissue (Nims et al., 1994). Some congeners like 3,3’,4,4’5-PnCB are specifically 
retained by the liver, due to binding to cytochrome P450 1A2 enzyme (Andersen et 
al., 1997; Andersen et al., 1993; DeVito et al., 1998; VanBirgelen et al., 1994a; 
Voorman and Aust, 1987; Yoshimura et al., 1984), resulting in liver to blood partition 
coefficients that are higher than expected based on the solubility of the PCB in the 
lipid fraction of both fractions.   
Physiology e.g. tissue volumes and perfusion rates, also plays a role in tissue 
distribution, (Birnbaum, 1983; Matthews and Tuey, 1980; Wyss et al., 1982; Wyss et al., 
1986). As PCBs accumulate in adipose tissue, the volume of the adipose tissue affects 
the tissue distribution of these congeners. A larger volume implies that a larger 
amount of the PCBs distribute to the adipose tissue (Birnbaum, 1983). This entails 
that the other organs or tissues receive a smaller fraction of the body burden. 
Compared to rats humans have larger fat depots. Thus, the tissue distribution in 
humans is expected to be different from rats. 
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Metabolism 
Metabolism of PCBs occurs mainly in the liver (Lutz et al., 1977; Matthews and 
Dedrick, 1984) and is achieved primarily by cytochrome P450 (CYP) enzymes 
(Matthews and Dedrick, 1984) by hydroxylating the PCBs. This is considered the rate 
limiting step in the elimination of PCBs (Lutz et al., 1977; Matthews and Dedrick, 
1984). Thus, after the initial hydroxylation the compound can be readily excreted or 
further metabolised. Further metabolism includes additional hydroxylation reactions 
or conjugation reactions with e.g. glutathione or glucuronic acid. These metabolites 
are excreted by urine or via the bile, into the feces. Some general conclusions, with 
respect to metabolism of PCBs, have been drawn (Matthews and Dedrick, 1984; Safe, 
1989):  
• Hydroxylation reactions are preferably directed to the para position in the least 
chlorinated phenyl-ring, except when this site is sterically hindered,  
• in lower chlorinated biphenyls the para positions of both rings and the carbon 
atoms that are para to the chlorine atoms are easily metabolised,  
• the presence of vicinal unsubstituted carbon atoms facilitates hydroxylation of 
PCBs,  
• the degree of chlorination on both rings is inversely related to the metabolic rate,  
• metabolism of individual PCBs is species dependent.  
 
In vitro studies using purified CYP enzymes showed that CYP2B enzymes 
catalysed the hydroxylation of ortho substituted PCBs while CYP1A enzymes catalysed 
preferably the hydroxylation of non-ortho substituted PCBs (Kaminsky et al., 1981). 
CYP2B1 preferably hydroxylated PCBs at the unchlorinated phenyl-ring while 
CYP1A1 showed an inclination towards the chlorinated phenyl ring (Kaminsky et al., 
1981). These results demonstrate that the hydroxylation of PCBs by CYPs is highly 
regio-selective and depends on the enzyme that catalyses the reaction. Thus, the 
metabolic rates of PCBs depend on the CYP composition in the liver and 
extrahepatic tissue as well as on the congener itself. 
Metabolism of PCBs in extrahepatic tissue has not been reported. However, the 
presence of various CYP enzymes in extrahepatic tissue like small intestine, kidney 
and lung suggest possible Phase I metabolism. Within the G.I-tract it has been 
reported that microflora can deconjugate conjugated PCBs (Bergman et al., 1982; 
Gustafsson et al., 1981), but hydroxylation of PCBs by microflora in the G.I-tract has 
not been reported. 
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Elimination of  metabolites 
The urine, bile and feces are the main routes of excretion of metabolised PCBs. 
The contribution of urinary excretion to the total excretion of PCBs decreases with 
increasing number of chlorine atoms in mammals, in favour of excretion via the feces 
(Fisher et al., 1989; Lutz et al., 1977; Lutz et al., 1984; Matthews and Anderson, 1975; 
Matthews and Tuey, 1980; Morales et al., 1979).  
Elimination of  parent compound 
PCBs are mainly excreted as metabolites but elimination of parent compound 
occurs as well. For the hardly metabolisable 2,2’,4,4’,5,5’-HxCB only 2 % of the dose 
was excreted in the feces as parent compound after 21 days and about 2 % as 
metabolite (Birnbaum, 1983). A different study with this PCB showed that the 
percentage of the dose excreted in the feces increased up to 12 % forty weeks after 
exposure (Muhlebach and Bickel, 1981). For slowly metabolisable PCBs the 
contribution of excretion of parent compound to the overall excretion is relatively 
high. Less then 10% of the dose of the readily metabolisable 2,2’, 3, 3’,6, 6’-HxCB is 
excreted as parent compound four days after exposure in the feces (Birnbaum, 1983). 
These results imply that excretion of parent compound contributes marginally to the 
total elimination of easily metabolisable PCBs. Taking into account the lifetime 
exposure of humans to PCBs with half-lives between 2 to 6 years, the excretion of 
parent compounds for the slowly metabolised PCBs might become relevant. A less 
continuous route of excretion is via lactation. Its contribution to the total excretion 
however, could be approximately 96 % of the total body burden during one lactation 
period, dependent on the species (Takagi et al., 1976; Vodicnik, 1986; Gallenberg et 
al., 1990; Gallenberg and Vodicnik, 1989). 
Pharmacokinetic modelling 
Kinetic processes can be described quantitatively using mathematical descriptions 
in pharmacokinetic models. Two main types of pharmacokinetic models can be 
distinguished: data based pharmacokinetic models and physiologically based 
pharmacokinetic (PB-PK) models. For a comprehensive review the reader is referred 
to the papers of Yang and Andersen (1994) and Krishnan and Andersen (1994). 
Data-based pharmacokinetic models represent the organism as one or more 
compartments. The parameters of the model are obtained by fitting the model to the 
kinetic data, and have no direct physiological or biological meaning. As a 
consequence, the parameter values are of limited value with respect to their biological 
meaning. They describe tissue or blood concentration of one particular experiment 
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and can not be used for extrapolation to other experimental conditions. The 
physiologically based models represent the organism as compartments that have a 
physiological meaning and are based on an anatomical description like tissue volume 
and blood flow. Furthermore, the model description includes biochemical processes 
like metabolism. These PB-PK models comprise many parameters. A large number of 
them can be obtained a priori from the literature like e.g. blood flows, cardiac output 
and tissue volumes, or can be determined experimentally or e.g. from in vitro 
experiments. The advantages of these physiologically based models are that they can 
forecast tissue concentrations under circumstances that have not been experimentally 
determined, e.g. different dose levels, different routes of exposure, or different 
exposure regimen. In addition, these models can also be used to extrapolate the 
kinetics to other species of species by scaling tissue volumes and blood flows, e.g. 
from rat to human (Krishnan and Andersen, 1994). Using this type of modelling the 
estimation of the tissue concentration is improved or at least the underlying 
assumptions are indicated.   
Parameterisation  
The partition coefficients (PC) quantify the distribution of chemicals between 
tissues and blood under steady state conditions. Great effort has been put into the 
development of methods to estimate or determine PCs on forehand for use in PB-
PK models. Different model approaches have been proposed to estimate PCs. These 
model approaches are based on distribution of a chemical between the lipids and the 
aqueous phase of a tissue and blood. This distribution is directed by the n-octanol to 
water partition coefficient (=Kow) (DeJongh et al., 1997; Haddad et al., 2000; Poulin 
and Theil, 2000). These models were validated for compounds, having a Log Kow 
between 2 to 5.  
Furthermore, in vitro methods were developed to determine PCs experimentally 
(Artola-Garicano et al., 2000; Jepson et al., 1994; Murphy et al., 1995). The in vitro 
methods for non-volatile chemicals measure the partitioning between tissue and 
saline or blood and saline. These PCs agreed well with values determined in vivo 
(Murphy et al., 1995). 
Many in vivo and in vitro methods have been described to determine metabolic 
parameters. For volatile chemicals independent metabolic parameters were obtained 
using closed chamber experiments. The change of chemical concentration in the 
chamber, was used to determine the uptake and the metabolism by the animal 
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(Andersen et al., 1980; Gargas et al., 1986). This procedure was suitable to obtain 
metabolic rate constants for volatile chemicals, which could be described by 
Michaelis-Menten kinetics.  
Another way to obtain independent metabolic parameter values is by in vitro 
studies. Subcellular fractions like microsomes, isolated cells, tissue slices or isolated 
perfused organs are used to determine metabolic rates. These systems differ in their 
degree of tissue or organ integrity. Therefore, it remains difficult to determine the 
relevance of the in vitro metabolic rates for the in vivo situation, e.g. scaling of 
metabolic rate constants in hepatic microsomal fractions that contain enzymes that 
are located in the endoplasmic reticulum to a whole liver. This scaling involves many 
uncertainties. For example the extrapolation of transport processes in the liver and in 
the in vitro system or in binding characteristics in vivo compared to in vitro. However, 
some studies showed the validity of in vitro metabolic rate constants to predict in vivo 
metabolic rates, using hepatocytes, liver slices or microsomal fractions (Carlile et al., 
1998; Hayes et al., 1995; Houston, 1994a; Houston, 1994b; Obach, 1997; Worboys et 
al., 1996; Worboys et al., 1997).  
Absorption rate constants and excretion rate constants can be determined in vivo 
and in vitro. In vivo absorption or excretion rates are determined by fitting a 
mathematical description to the experimental data, which are in general tissue or 
blood concentration data. In vitro experiments involve isolated tissue preparation like 
for example skin slices. For PCBs a few in vitro studies have been performed to 
determine dermal absorption rates (Fisher et al., 1989; Wester et al., 1983). For 
intestinal absorption also in vitro studies have been done (Dulfer et al., 1996; Oomen, 
2000) using Caco2-cells.  
SCOPE OF THIS THESIS 
TCBTs were produced to replace PCBs because congeners of the latter group 
have been accumulating in biota and have been inducing toxic effects. Accumulation 
of PCBs is partly caused by their resistance towards metabolism. To study the 
possible accumulation of TCBTs in biota, the rate of metabolism can be used to 
estimate their potential to accumulate in biota. CYP enzymes catalyse the 
hydroxylation reaction of PCBs, which is assumed to be rate limiting with respect to 
the elimination of these compounds. Based on the chemical structure of the TCBTs it 
is fair to assume that CYP enzymes also hydroxylate TCBTs, and that this is rate 
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limiting the elimination as well. Hence, metabolic rate constants of TCBTs were 
determined in vitro and compared to metabolic rates of PCBs. The TCBTs that could 
adopt a coplanar conformation (3, 3’, 4, 4’-Cl4-2-methyl- and 3, 3’, 4, 4’-Cl4-5-methyl-
chlorobenzyltoluene, referred to as TCBT 87 and TCBT 88, respectively) were 
examined in these experiments because of their supposed interaction with the Ah-
receptor, which is related to dioxin-like toxicity. TCBT 94 (3, 3’, 4’, 5-Cl4-4-methyl-
chlorobenzyltoluene) was included as well, representing differently substituted 
TCBTs. Chapter 2 describes an in vitro method to determine metabolic rate constants 
of TCBTs using rat and fish hepatic microsomes. This method was also used in 
chapter 3 and 4. In these chapters metabolic rates of TCBTs were compared with 
tetra, penta and hexa chlorinated PCBs using microsomes from rat (Chapter 3) and 
humans (Chapter 4). Many tissues express various CYPs that could be involved in the 
metabolism of the TCBTs or PCBs. Thus, identifying the CYPs provides insight in 
the extrahepatic tissues contributing to their metabolism. Chapter 3 describes the 
identification of CYPs metabolising the TCBTs and the PCBs in the rat by 
correlation analysis. Rats were pretreated with different inducing agents to increase 
the activity of specific CYPs. Statistical analysis of the correlations between specific 
enzyme activities and metabolic rate constants of the TCBTs and the PCBs revealed 
the possible involvement of a specific CYP. Subsequent selective inhibition of 
correlating CYP confirmed the involvement of this enzyme. In chapter 4 the identity 
of the CYPs in humans were also determined by correlation analysis using human 
liver microsomes. 
An additional goal of this study is to gain more insight in the kinetics of three 
TCBTs using PB-PK modelling. Chapter 5 describes the in vivo kinetics of these 
TCBTs after a single intravenous bolus injection. The tissue concentration data were 
used to calibrate the PB-PK model. To determine the value of the in vitro metabolic 
rate constants from hepatic microsomes for the parameterisation of PB-PK models, 
the in vitro metabolic rate constants from chapter 2 were compared to the in vivo 
values. In general, the exposure of mammals to these xenobiotics occurs mainly via 
oral ingestion. This exposure route might influence the bioavailability by reduced 
absorption or by first-pass metabolism. In chapter 6 the oral bioavailability of some 
TCBTs and some PCBs have been determined. Rats were exposed to a single 
intravenous injection or a single oral dose of a mixture of PCBs and TCBTs. Tissue 
concentrations were determined and analysed by a PB-PK model for the TCBTs and 
for the PCBs. The studies described in chapter 5 and 6 provide insight in the in vivo 
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behaviour of highly chlorinated lipophilic substances in the rat. The PB-PK model 
for the PCBs and the TCBTs in the rat was extrapolated to humans to estimate the 
tissue concentrations for different exposure regimen (Chapter 7). The tissue volumes 
and the blood flows in the rat were adjusted to the human values. The metabolic rate 
constants from the human liver microsomes were extrapolated to in vivo metabolic 
rate constants taking into account the microsomal volume in the human liver. With 
this model, tissue levels of TCBTs in humans after a single or multiple doses were 
estimated (Chapter 7) and compared to PCB levels observed in human tissues.
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CHAPTER 2 
BIOTRANSFORMATION RATES OF UGILEC141 
(TETRACHLOROBENZYLTOLUENES) IN RAT AND TROUT 
MICROSOMES 
 
 
 
 
H.J. Kramer, M. VandenBerg, R-J DeLang, L. Brandsma, and J. DeJongh 
 
Chemosphere (2000), 40, p.1283-1288 
ABSTRACT 
In vitro biotransformation rate constants of tetrachlorobenzyltoluene (TCBT) isomers 
3,3’,4,4’-Cl4-2-Me (TCBT 87), 3,3’,4,4’-Cl4-5-Me (TCBT 88), and 3,3’,4’,5-Cl4-4-Me (TCBT 94) 
were determined using trout and rat hepatic microsomes. The disappearance of the TCBTs 
from the in vitro system followed first-order kinetics. The estimated biotransformation 
constants (k) for the rat ranged from 0.96 to 4.14 h-1. Biotransformation rates for trout 
microsomes were much lower and ranged from 0.009 to 0.017 h-1.
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INTRODUCTION 
Ugilec 141, an industrial mixture of 69 tetrachlorobenzyltoluene (TCBT) 
isomers (Ehmann and Ballschmiter, 1989), was introduced as a replacement for 
polychlorinated biphenyls (PCBs) on the European market in the early 1980s. The 
use of PCBs was prohibited because of their environmental persistence and their 
toxicity. Due to structural and physicochemical similarities with PCBs, food chain 
accumulation of TCBTs was expected (VanHaelst, 1996) and therefore its use was 
prohibited in the European Union. In fish levels up to 24.9 mg.kg-1 fish tissue have 
been reported (Fuerst et al., 1987b). Weak accumulation of Ugilec 141® has been 
demonstrated in fish and rat (Bouraly, 1989). Bioconcentration factors (BCFs) for 
Ugilec 141® in rat liver are lower than for Fenclor 54®, a PCB mixture (Leoni et al., 
1988). BCFs in the guppy (Poecilia reticulata) were lower for six TCBTs than for 2, 2’, 
4, 4’, 5, 5’-hexachlorobiphenyl (VanHaelst et al., 1996a). Ugilec 141®, Aroclor 1254® 
and 3, 3’, 4, 4’-tetrachlorobiphenyl (PCB 77), induced comparable biochemical 
changes such as enzyme induction in both mice and rats, although the effects were 
less pronounced for Ugilec 141® (Murk et al., 1991; VonMeyerinck et al., 1990). It 
was hypothesized that the limited accumulation as well as the limited cytochrome 
P450 (CYP) induction is explained by a relatively rapid biotransformation of TCBTs 
(Murk et al., 1991; VonMeyerinck et al., 1990). 
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Figure 1. Chemical structure of three TCBT isomers. 
The relationship between biotransformation and accumulation has been well 
known for PCBs (Muehlebach et al., 1991). In contrast, little is known about 
biotransformation of TCBTs. In order to explain the limited accumulation in greater 
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detail, we determined biotransformation rate constants of three TCBT isomers (Fig. 
1) in rat and trout microsomes as representatives of mammalian and aquatic species.  
The theoretical affinity of all TCBTs for the Ah-receptor was previously 
estimated by computer simulation (VanHaelst et al., 1997). TCBTs 87 and 88 showed 
a high probability to fit into the Ah-receptor and may therefore exhibit some forms 
of dioxin-like toxicity, which can be relevant for risk assessment. 
MATERIALS AND METHODS 
Chemicals 
The 3,3’,4,4’-Cl4-2-Me- (TCBT 87), 3,3’4,4’-Cl4-5-Me- (TCBT 88), and 3,3’,4’,5-
Cl4-4-Me- (TCBT 94) tetrachlorobenzyltoluene (purity >99%) were synthesised as 
described previously (DeLang et al., 1998). The 4,4’-dichlorobiphenyl (PCB 15) and 
2,2’,4,4’,5,5’-Hexachlorobiphenyl (PCB 153) (purity >99%) were obtained from Dr 
Ehrenstorfer GmbH (Ausburg, Germany). NADP (β-NADP), glucose-6-phosphate-
dehydrogenase (G6PDH) (140 U/mg), and glucose-6-phosphate (G6P) were 
purchased from Boehringer-Mannheim (Almere, The Netherlands). n-Hexane, 
methanol, acetone, and glycerol (analytical grade) were obtained from J.T. Baker B.V. 
(Deventer, The Netherlands). The incubation buffer (KPi, pH=7.4) consisted of 0.08 
M K2HPO4, 0.01 M Na-EDTA, and 0.08 M KH2PO4 (Merck, Amsterdam, The 
Netherlands). Resorufin, ethoxyresorufin, pentoxyresorufin, methoxyresorufin and 
bovine serum albumin (BSA) were purchased from Sigma Chemical Co. (St. Louis, 
USA). 
Animals 
Male Wistar CPB:uWU rats (250-300 g) from Central Animal Laboratory (Utrecht 
University) remained untreated or were given a single intraperitoneal dose of either β-
naphtoflavone (BNF; 67 mg/kg in arachid oil) or phenobarbital (PB; 64 mg/kg in  
0.9 % saline). The livers were removed 24 hours later under anaesthesia (Nembutal, 
200 mg/kg) after in situ perfusion of the liver via the portal vein with 0.9 % saline. 
Rainbow trout (Oncorhynchus mykiss) (300-400 g), purchased from a local hatchery, 
were reared at 15°C. Trout were killed and the livers were quickly removed and 
weighed.  
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Preparation of  microsomes 
Isolation of microsomes and determination of protein content was performed as 
described previously (Lowry et al., 1951; Rutten et al., 1987).  
Biotransformation assay 
The present method was based on a previously described, qualitative 
biotransformation assay (Boon et al., 1998). All substrates were dissolved in acetone. 
The final solvent concentration was limited to 1.6 % to prevent influence on the 
microsomal enzyme activity (Cotreaubibbo et al., 1996). The three TCBT substrates 
were incubated in glass test tubes in a gently shaking water bath at 37°C (rat) or 15°C 
(trout). The incubation mixture (final volume 1220 µl) consisted of KPi buffer, a 
regenerating system (2.5 mM MgCl2, 8 mM G6P, 4.3 U G6PDH), TCBT substrate 
(final concentrations 5.1, 26, 51 or 290 nM), and 1 mg microsomal protein. The 
TCBTs were incubated individually with PCB 153 and 15 as a negative and positive 
biotransformation control, respectively. A mixture of TCBTs 87, 94 and both PCBs, 
which were all present at a concentration of 290 nM was incubated with rat 
microsomes to detect possible substrate competition. The biotransformation reaction 
was started by adding 2 mM NADP (final concentration). Instead of NADP, 100 µl 
KPi was added to obtain data for non-enzymatic disappearance of TCBT. The 
biotransformation reaction was stopped at 0, 5, 15, 30, 40, 60 or 90 minutes (rat) and 
at 0, 4, 8 and 11 hours (trout) by adding 1000 µl ice cold MeOH to the incubation 
mixture. 
Extraction 
Substrates were extracted from the incubation buffer by three n-hexane washings 
(2 ml) using a Vortex shaker (Boom B.V. Meppel, the Netherlands). The organic 
phase was collected after centrifugation (1000 g, 2 min). After evaporation (T = 20 
°C) of the hexane, the samples were redissolved in 100 µl n-hexane. Recovery of PCB 
153 and TCBTs from control incubations (without NADP) were always > 90%. 
GC-analysis 
Extracts were analysed using a Carlo-Erba Mega Series HR-gas chromatograph, 
equipped with a 63Ni-Electron Capture Detector and a DB-5 column (15 m, dl=0.25 
µm, ID=0.32 mm). Injector temperature: 225 °C; split ratio 30 (top split =60 ml/min 
and bottom split: 2 ml/min) injection volume: 2 µl; temperature program: 1 min at  
225 °C; 5 min at 250 °C, rate 30°C/min. The detection limit was 20 pg. 
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The individual data were plotted using Slidewrite for Windows 4.0 (Advanced 
Graphics Software Inc., Carlsbad, USA) and fitted according to first-order kinetics: 
kteAtA −= 0)(    eq. 1 
where A is the amount at time t, A0 is the amount at t=0 defined as 100%, and k 
(time-1) is the biotransformation rate constant. Statistically significant differences 
between the estimates of the biotransformation rate constants were determined by 
Student t-test with Bonferroni adjustment (α=0.05/3). 
Enzyme activity assays 
Enzyme activity of control, BNF and PB-induced microsomes was measured 
using pentoxy-, ethoxy-, and methoxyresorfin (=PROD, EROD, MROD, 
respectively) as model substrates for CYP 2B and 1A activity (Burke et al., 1985). 
Microsomes from untreated animals were incubated for 140 min at 37 °C (rat) or 12 
hours at 15 °C (trout). Their activity was monitored by measuring EROD activity, as 
indicator for the possible loss of microsomal enzyme activity over time.  
RESULTS 
Biotransformation appeared to be linearly dependent on the substrate 
concentration (5-290 nM) for each TCBT isomer at concentrations near aqueous 
solubility (Fig. 2).  
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Figure 2. Concentration dependency of the biotransformation of TCBT 88 after 20 minutes of 
incubation using rat hepatic microsomes. Disappearance of parent compound (TCBT 88) from 
the incubation mixture was used as measure for biotransformation. Each data point is the 
average of three determinations with standard error. 
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Biotransformation rate constants (k) and half-lives were derived from plots 
showing the relative disappearance of each isomer (Table 1; Fig. 3). 
Biotransformation of the positive control (PCB 15) was only detected in control 
samples (no NADP added) and in samples from incubations with rat microsomes at 
t=0, while for trout microsomes 60% of PCB 15 was recovered after 4 hours of 
incubation. The average non-enzymatic disappearance of TCBT was 6.0 ± 2.1 % for 
both species. For the rat, significant differences in biotransformation rates were 
observed among the individual isomers (TCBT 94 > 88 >> 87).  
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Figure 3. Disappearance curves of three TCBT isomers using rat (A) and trout (B) hepatic 
microsomes. Incubations (average ± SD, n=3) were performed at 37 °C (rat) or 15 °C (trout).  
When a mixture of TCBT 87 and 94, PCB 15 and 153 was incubated, 
biotransformation rate constants were not significantly different from incubation 
mixtures with the single isomers (data not shown). Thus, no substrate competition 
occurred up to concentrations of 290 nM. 
The data for trout do not show unambiguously that biotransformation of TCBT 
occurs. The k-values for trout microsomes are two to three orders of magnitude 
lower than for rat microsomes (Table 1). Incubating trout microsomes at higher 
temperatures (15, 22 and 26 °C) did not influence the biotransformation rates (data 
not shown). Due to extremely low biotransformation of TCBTs by trout hepatic 
microsomes within the observed 11 h incubation period, no significantly different 
biotransformation rates among isomers could be observed. 
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Table 1. First-order biotransformation rate constants k (95% confidence interval), and half-lives 
for three TCBTs for rat and rainbow trout. 
TCBT k (upper limit of 95% C.I.) Half-life (min) 
 Rat (min-1) Trout (h-1) Rat (min) Trout (min) 
87 0.016* (0.021) 0.009 (0.015) 43 4.8x103 
88 0.063 (0.074) 0.012 (0.015) 11 3.5x103 
94 0.069 (0.096) 0.018 (0.017) 10 2.4x103  
* TCBT 87 is statistically significantly different from TCBT 88 and 94 (p<0.001) 
 
The present method led to accurate determination of k-values for 
biotransformation of all three isomers in the rat, as illustrated by the narrow 95% 
confidence intervals. For trout, where biotransformation was relatively slow, the 
method resulted in much larger confidence intervals. 
Table 2. Influence of phenobarbital or β-naphtoflavone pretreatment on enzyme activities of rat 
hepatic microsomes (pmol.min-1.mg-1). 
Treatment EROD MROD PROD 
Untreated 26.9 80.1 9.9 
Phenobarbital 15.7 27.8 55.5 
β-naphtoflavone 48.1 225.3 14.6 
 
Pretreatment of rats with either PB or BNF led to induction of microsomal 
activity towards the model substrates for CYP1A1, 1A2 and 2B1 of up to five times 
(Table 2). PB induced microsomes metabolised the TCBTs 10 to 16 times more 
rapidly than the corresponding control microsomes, while BNF induced microsomes 
metabolised TCBTs only 1.5 to 1.7 times more rapidly (Fig. 4). Loss of 
biotransformation activity of microsomes overtime was reflected by a decrease of 
EROD activity (Fig. 5). For the rat, a gradual decrease to 75% of the initial activity 
was observed within 140 min. For trout, the activity decreased to 50% in 4 hours. 
Thereafter, the average activity remained constant. 
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Figure 4. Effect on the disappearance of TCBT using hepatic microsomes from rats pretreated 
with PB and BNF compared to the disappearance of TCBT using hepatic microsomes from 
untreated rats (C). Each bar represents the mean (±SD) of three determinations. 
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Figure 5. Relative decrease of EROD activity in rat (left panel) and trout (right panel) hepatic 
microsomes during the incubation period of the TCBT biotransformation assay. Each bar 
represents the mean (±SD) of three determinations. 
DISCUSSION 
Biotransformation rate constants of three TCBT isomers were obtained by 
measuring the disappearance of the parent compound from the in vitro system using 
microsomes from rat and rainbow trout. The non-enzymatic elimination attributed to 
only 6 % of the overall disappearance after 90 minutes in rat hepatic microsomes. 
Thus, disappearance of TCBT was almost entirely due to enzymatic 
biotransformation. The non-enzymatic elimination in trout was also 6 %, while the 
overall disappearance of TCBTs was maximally 10 % after 11 hours with relatively 
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high standard deviations. The k-values for trout did not differ significantly from zero 
and therefore the biotransformation rates can be considered semi-quantitative. 
For PCBs, the metabolic rate is inversely correlated with the degree of 
chlorination (Borlakoglu and Wilkins, 1993; Grant et al., 1972; Hutzinger et al., 1972; 
Mehendale, 1976). Therefore we wanted to compare our in vitro biotransformation 
rates with metabolic rates for tetrachlorinated PCBs. However the availability of such 
data was limited. For 2,2’,3,5,5’,6-HCB (PCB 151), a Vmax of 0.45 pmol.min-1.mg-1 
microsomal protein was determined based on the formation of PCB 151 metabolites 
(Borlakoglu et al., 1990a). BNF induced microsomes (123 fold EROD induction 
relative to control microsomes) metabolised 3,3’,4,4’-TCB (PCB 77) at a Vmax of 240 
pmol.min-1.mg-1 (Morse et al., 1995). Assuming linearity between the induction level 
and biotransformation rate, this implies a Vmax of 1.95 pmol.min-1.mg-1. However, 
this assumption may overestimate metabolism, as EROD activity does not necessarily 
reflect the specific enzymes that metabolise PCB 77. In the present study, the 
biotransformation rate was linear between 6-300 pmol parent compound per 
incubation (Fig. 2). For TCBT 88 (k = 0.063 min-1.mg-1), the biotransformation rate 
would be 18.9 pmol.min-1.mg-1 microsomal protein at 300 pmol. The previous 
estimation suggests that the three TCBTs are metabolised more rapidly than either 
PCBs 77 or 151. 
In the present study, large species differences were observed in the TCBT 
biotransformation rates between rat and trout microsomes (Table 1; Fig. 3). 
Metabolism of xenobiotics is generally higher in rats than in fish (Sijm and 
Opperhuizen, 1989). This is explained in part by a 30-60% higher total CYP 
concentration and a 3-36 % higher CYP activity per mg microsomal protein in 
mammalians than in fish (Sijm and Opperhuizen, 1989). However, these general 
observations do not explain the specific differences in TCBT metabolism between rat 
and trout. It was presently observed in rat microsomes (Fig. 4) that TCBTs are more 
efficiently metabolised by PB inducible CYPs (e.g. CYP2B) than by BNF inducible 
CYPs (e.g. CYP1A). This suggests that the limited biotransformation of the TCBT 
isomers in trout microsomes might be explained by the absence, or limited activity, of 
CYP2B enzymes in trout (Stegeman, 1989). Although an enzyme that 
immunologically cross-reacts with rat CYP2B proteins has been found in trout, it 
remains unclear whether this protein is functionally comparable to rat CYP2B 
enzymes (Stegeman, 1989).  
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For the structurally related PCB 77, it was recently demonstrated that CYP1A is 
involved in its metabolism in marine scup (Stenotomus chrysops). In contrast, CYP1A 
was identified in trout hepatic microsomes but PCB 77 was not metabolised 
measurably in this system (Murk et al., 1994). This may explain the relatively high 
accumulation of PCB 77 in environmental fish tissue samples (Boer et al., 1993). 
Thus, our present findings on the slow biotransformation rate of TCBTs in trout 
suggest a similar accumulation potential for these compounds in fish as for PCB 77. 
In conclusion, the present study has reported approximately 100-fold differences 
in in vitro biotransformation rates of three TCBT isomers between rat and trout 
microsomes. These differences may result in a relatively high accumulation of TCBTs 
in trout. First-order biotransformation kinetics of these TCBTs were observed in the 
rat at concentrations near their aqueous solubility. The substantially lower 
biotransformation rate of TCBTs in trout compared to rat is probably explained by 
relatively lower or lack of CYP2B levels in trout, but this awaits further study.  
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CHAPTER 3 
METABOLIC RATE CONSTANTS OF UGILEC 141 ISOMERS 
AND POLYCHLORINATED BIPHENYL CONGENERS USING 
RAT HEPATIC MICROSOMES AND THE IDENTIFICATION OF 
INVOLVED CYTOCHROME P450 ENZYMES 
 
H.J. Kramer, H. Drenth, R. Fleuren, S. Hengeveld, W. Seinen, and M. VandenBerg 
 
In part published in: Organohalogen Compounds, 1999, vol. 42, p.185-189  
 
ABSTRACT 
Ugilec 141, consisting of tetrachlorobenzyltoluenes (TCBTs) was introduced as a 
replacement for technical mixtures of polychlorinated biphenyls (PCBs). Accumulation of 
these TCBTs in biota occurred, indicating that their metabolism is limited. In the present 
study rat hepatic microsomes were used to determine metabolic rate constants for TCBTs 
and PCBs. Additionally, cytochrome P450 (CYP) enzymes involved in the metabolism of 
three TCBTs and eight PCBs were identified using correlation analysis. Rats were 
pretreated with specific cytochrome P450 inducers like: phenobarbital (CYP2B1/2), clofibric 
acid (CYP4A1), isosafrole (CYP1A2), β-naphthoflavone (CYP1A1), and dexamethasone 
(CYP3A1/2). CYP enzyme activities of the isolated microsomes as well as the metabolic 
rate constants of the TCBTs and the PCBs were determined and submitted to correlation 
analysis. Statistical significant correlations were confirmed using specific CYP inhibitors like 
orphenadrine (CYP2B1 inhibitor), Troleandomycin (CYP3A1 inhibitor) and α-
Naphthoflavone (CYP1A2 inhibitor). It was shown that TCBTs were 2 to 50 times faster 
metabolised than PCBs. CYP 2B1 and CYP2B2 play a major role in the metabolism of the 
TCBTs. Involvement of CYP3A1, 3A2, 2A1 and 2A2 was indicated as well, but was less 
pronounced. Similar enzymes were involved in the metabolism of PCB 136. CYP1A1 and 
1A2 played a major role in the metabolism of PCB 77. In conclusion, the more rapid 
metabolism of the TCBTs suggests that these compounds accumulate less than the PCBs. 
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INTRODUCTION 
Ugilec 141, an industrial mixture of 69 tetrachlorobenzyltoluenes (TCBTs) 
(Ehmann and Ballschmiter, 1989), was introduced as an alternative for 
polychlorinated biphenyls (PCBs) in hydraulic devices. Following the commercial 
introduction of TCBTs, tissue levels up to 25 mg. kg-1 fish were reported (Fuerst et 
al., 1987b), indicating leakage of TCBTs into the environment and accumulation in 
the food chain, similar to PCBs. These factors resulted in 1994 in the prohibition on 
the use of TCBT in the European Union. 
PCBs are ubiquitously present in the environment and accumulate in adipose 
tissue of species at different levels of the food chain. This bioaccumulation can be 
explained by slow elimination caused by slow biotransformation of PCBs. 
Biotransformation of PCBs is mainly performed in the liver (Lutz et al., 1977; 
Matthews and Dedrick, 1984). The rate limiting step in the metabolism of PCBs is 
assumed to be the hydroxylation or oxidation by cytochrome P450 (CYP) enzymes 
(Lutz et al., 1977; Matthews and Dedrick, 1984). TCBTs were shown to be 
metabolised by these enzymes as well (Kramer et al., 2000b). 
The liver contains many CYPs in various amounts. Insight in the identity of 
CYPs, involved in the metabolism of PCBs and TCBTs, would improve insight in the 
toxicokinetics of these compounds, e.g. the contribution of other tissues except the 
liver to the metabolism could be determined this way. 
In the present study in vitro metabolic rates of TCBTs and PCBs were compared 
to determine differences in possible accumulation of both categories of compounds. 
Furthermore, CYPs involved in the metabolism of PCBs and TCBTs were identified 
by analysis of the correlations between specific CYP enzyme activities and the 
metabolic rates of individual PCB and TCBT congeners. When a specific CYP 
significantly correlates with the metabolic rate of a compound then it is likely that this 
enzyme is involved in its metabolism (Clarke, 1998; Parkinson, 1996). In order to 
increase the power of the correlation analysis, a broad range of CYP enzyme activities 
is needed. In the present study this condition was met by using rat hepatic 
microsomes from rats pretreated with agents that specifically induce CYPs. In 
addition, to confirm the involvement of certain CYPs, the effect of specific inhibitors 
on the metabolic rate was studied. 
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MATERIALS AND METHODS 
Chemicals 
TCBT isomers 3,3’,4,4’-Cl4-2-Me- (TCBT 87), 3,3’4,4’-Cl4-5-Me- (TCBT 88), and 
3,3’,4’,5-Cl4-4-Me-tetrachlorobenzyltoluene (TCBT 94) were kindly provided by Prof. 
L. Brandsma from the department of Preparative Organic Synthesis of the Chemistry 
Faculty of Utrecht University. Their purity was >95 % as described by DeLang et al. 
(1998). The isomers are numbered according to Ehmann and Ballschmiter (1989). 
PCB 2,2’,5,5’-TCB (PCB 52), 3,3’,4,4’-TCB (PCB 77), 3,3’,5,5’-TCB (PCB 80), 
2,2’,4,5,5’-PnCB (PCB 101), 2,3’,4,4’,5 PnCB (PCB 118), 3,3’,4,4’,5-PnCB (PCB 126), 
2,2’,3,3’,6,6’-HxCB (PCB 136), 2,2’,4,4’,5,5’-HxCB (PCB 153), 2,2’,4,4’,6,6’-HxCB 
(PCB 155), 2,3,3’,4,4’,5-HxCB (PCB 157) and 2,2’,3,4,4’,5,5’-HpCB (PCB 180) 
congeners were obtained from Dr Ehrenstorfer (Augsburg, Germany). Their purity 
was >98 %. Analytical grade n-hexane, acetone, methanol, acetonitrile, and 
dichloromethane were obtained from J.T. Baker (Deventer, The Netherlands). 
Glucose-6-phosphate (G6P), glucose-6-phosphate dehydrogenase (G6PDH), and 
NADP were obtained from Boehringer (Mannheim, Germany). MgCl2, K2HPO4, and 
NaH2PO4 were obtained from Merck (Darmstadt, Germany). β-naphthoflavone 
(BNF), isosafrole (ISO), clofibric acid (CLO), sodiumphenobarbital (PB), 
dexamethasone (DEX) , 8-methoxsalen (MOP), troleandomycin (TAO), α-
naphthoflavone (ANF), ethoxyresorufin, methoxyresorufin, pentoxyresorufin, 
resorufin, and lauric acid, were obtained from Sigma (St. Louis, MO., USA). 
Orphenadrine (ORP) was purchased from Fluka AG (Basel, Switzerland ). 
Equipment 
A HPLC system from Gynkotek with a P580HPG pump and a Basic Marathon 
autosampler from Separations (H.I. Ambacht, The Netherlands) was used, equipped 
with an UVD170S UV detector from Separations (H.I. Ambacht, The Netherlands), 
or a Kontron instruments SFM25 fluorescence detector from Beun de Ronde 
(Abcoude, The Netherlands). The HPLC was equipped with a Chromsep C18 column 
(200 × 3 mm i.d., 5 µm particles) preceded by a 10 mm guard column packed with the 
same material (Chrompack, Middelburg, The Netherlands). Spectrofluorimetry was 
performed using a Cytofluor 2300 (Millipore, USA) with excitation wavelength of 530 
nm and an emission wavelength of 590 nm. 
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Animal treatment 
Male and female CPB:uWU rats were obtained from the Central Animal 
Laboratory (Utrecht University). Rats were acclimatised for a week, prior to 
treatment. Male and female rats remained untreated or were dosed intraperitoneally 
for four consecutive days with the following CYP inducers, dissolved in corn oil or 
indicated otherwise: 40 (mg/kg/d) BNF (CYP1A1), 75 mg/kg/d PB in saline 
(CYP2B1/2), 230 mg/kg/d ISO (CYP1A2), 300 mg/kg/d CLO (CYP4A1), or 75 
mg/kg/d DEX (CYP3A1/2). Livers of the individual rats were removed 24 hours 
after the last dose and perfused with ice cold saline until all blood was removed and 
stored at –80 °C till further use. 
About 3 to 4 gram liver was used for the isolation of microsomes as described by 
Rutten et al. (1987). The protein content was determined in triplicate according to 
Bradford (1976) using a calibration curve with bovine serum albumin as a standard.  
Microsomal CYP activities 
The alkoxyresorufine O-dealkylase (=AROD) activity of the isolated microsomes 
were determined in triplicate, using ethoxyresorufin (CYP1A1), methoxyresorufin 
(CYP1A2) and pentoxyresorufin (CYP2B1/2) according to Burke et al. (1985). One 
mg microsomal protein was incubated with the alkoxyresorufin substrate in a 0.05 M 
Phosphate buffer (pH=8.0). The reaction started by adding 50 µl of a NADPH-
regenerating system consisting of 1 µmol NADP, 5 µmol G6P, 0.95 Units G6PDH 
and 3 µmol MgCl2. 
Testosterone-hydroxylation assay and analysis of metabolites was performed as 
described by Wortelboer et al. (1990), using a NADPH regenerating system as 
described for AROD activities.  
Lauric acid hydroxylation activity, which is indicative for CYP 4A1, was 
determined according to Jansen and DeFluiter (1992). 
Characterisation of  differentially induced microsomes 
The inducing agents increased a broad range of enzyme activities as can be 
deferred from the relative induction of the indicative CYP activities (Table 1). These 
results are in coherence with earlier results (Wortelboer et al., 1991). 
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Table 1. Enzyme activities of microsomes from untreated male (M) and female (F) rat and the 
relative induction of microsomes isolated after pretreatment with inducers.  
Inducer Enzyme activity Specific 
CYP 
Activity untreated 
rat (pmol.min-1.mg 
protein-1) 
Relative induction 
specific CYP 
activity 
   M F M F 
β-naphthoflavone EROD 1A1 39 54 89 51 
Isosafrole MROD 1A2 50 56 82 18 
Phenobarbital PROD 2B1/2 7 5 14 7 
Dexamethasone Testosterone-15 
β-hydroxylase 
3A1/2 369 41 11 88 
Clofibric acid Lauric acid-12-
hydroxylase 
4A1 245 269 7 5 
Characterisation inhibitors 
Orphenadrine (ORP), 8-Methoxsalen (MOP), and Troleandomycin (TAO) were 
used to inhibit the activities of: CYP2B1/2 (ORP), CYP 2A (MOP) CYP3A1/2 
(TAO), respectively (Koenigs et al., 1997; Murray et al., 1997; Reidy et al., 1989; 
Watanabe et al., 1999). Testosterone hydroxylation incubations were performed using 
microsomes from PB treated rats with different inhibitor concentrations (ORP 0-15-
60-90-300 µM, MOP 0-5-15-30-60 µM and TAO 0-15-30-90-180 µM) to select the 
most specific inhibitor concentration. Incubations with 2 % (v/v) methanol were 
performed to eliminate possible solvent effects for ORP and TAO. ORP, MOP and 
TAO were pre-incubated for 15 minutes at 37 °C with microsomes from a male rat 
pretreated with PB in the presence of NADPH-regenerating system.  
In vitro metabolism of  TCBT and PCB 
In vitro metabolic rate constants were determined according to (Boon et al., 1998) 
and Kramer et al. (2000b) with minor adaptations. Testing the effect of protein 
concentration on the metabolic rate showed that metabolic rate was linear at 
concentrations over 0.5 mg/ml. To check the mass balance, PCB 153 (5 ng/µl) was 
added prior to the incubation. Incubations were performed in triplicate at 37 °C, 
using one mg protein in 0.95 ml 0.05 M phosphate buffer (pH=7.4) with a mixture of 
TCBT 87, 88, 94 or PCB 52, 77, 80, 101, 118, 126, 136, 155, and 180 at 
concentrations of 50 ng/ml. The metabolism started by adding 50 µl NADPH 
regenerating system (similar to testosterone assay). At 4 time points (t=0-150 
minutes) 200 µl aliquots were pipetted in a 1 ml MeOH:buffer solution (85:15 v/v). 
TCBTs were extracted with 4 ml n-hexane (recovery >90 %) and the PCBs twice 
with 3 ml n-hexane (recovery >90 %). The organic phase was collected and 100 µl of 
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the volume standard (1.5 mg/l PCB 157) was applied. The samples were evaporated 
at room temperature to approximately 500 µl and were subsequently analysed. 
Inhibition experiments were performed in triplicate at 37°C. 60 µM ORP or 30 
µM TAO were preincubated in 1 ml 0.05 M phosphate buffer (pH=7.4), 1 mg 
microsomes from PB treated male rat and 50 µl NADPH regenerating system during 
15 min. The metabolism of TCBT or PCB started by adding 5 µl of the TCBT or 
PCB solution (10 ng/µl acetone). 0.5 µM of ANF, a CYP1A2 inhibitor (Newton et al., 
1995) was co-incubated with TCBTs and PCBs without pre-incubation using 
microsomes from BNF pretreated male rat. 
GC analysis 
The samples were analysed on a Carlo Erba Mega 5360 HRGC-63Ni ECD 
equipped with a 15 m DB5 column (ID 0.32 mm, film thickness 0.25 µm). TCBTs 
were analysed using split injection with a split ratio of 30 (Tinjector= 250 °C, 
Tcolumn= 250 °C). PCB samples were analysed using split-less injection (Tinjector= 
250 °C) according to the following temperature program: 2 min at 70 °C, then to 255 
°C at a rate of 20 °C/min, then 5 min at 255 °C, then to 280 °C at 30 °C/min, finally 
4 min at 280 °C. Peak areas were determined. 
Calculation of  metabolic rate constant  
Disappearance of parent compound relative to PCB 153 follows a first-order 
process. The ratio of the peak areas of the TCBTs or PCBs were logarithmically 
transformed and submitted to linear regression to time. The slope represented the 
metabolic rate constant (k; min-1.mg protein-1). Statistically significant (p<0.05) k 
values were used in the correlation analysis. Since the variation in the method is about 
6 % (Kramer et al., 2000b) an estimate of the lowest detectable k after 150 minutes 
was 4*10-4 min-1. mg protein-1. It has been observed that microsomes from PB 
pretreated rat can metabolise 8 µM PCB 153 at 1 pmol.min-1.mg protein-1 (Duignan et 
al., 1987). At this concentration metabolism seems not to be saturated. Thus, at 250 
nM the metabolic rate would be 0.03 pmol min-1.mg protein-1. This implies that after 
150 min 5 pmol is metabolised. In this case the corresponding metabolic rate 
constant is smaller than the lowest detectable k of 4*10-4 min-1.mg protein-1. Thus, 
metabolism of PCB 153 is not detectable in our system. As a consequence, PCB 153 
is considered useful to check the mass balance of the system. 
The effect of an inhibitor on k was calculated according to equation 1 
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%100*%
solvent
inhibitorsolvent
k
kkinhibition −=   eq. 1 
Correlation analysis 
CYP activities were correlated with k values for TCBTs and PCBs. Spearman’s 
correlation coefficients were calculated using SPSS 7.5 for Windows (Chicago Il. 
USA) Correlations were considered to be statistically significant when α<0.05. 
RESULTS 
Metabolic rate constants  
In vitro metabolism of the TCBTs and PCBs could be described by first order 
kinetics as illustrated for TCBT 88; Microsomes from rats pretreated with 
phenobarbital increased the metabolic rate of TCBT 88 relative to microsomes of 
untreated rats (Fig. 1). Similar plots were obtained for the other congeners (plots not 
shown). Table 2 presents the first-order metabolic rate constants for the microsomal 
fractions of untreated and with inducer pretreated rats. 
0 10 20 30
time (min)
-2
-1
0
1
na
tu
ra
l l
og
  r
el
at
iv
e 
ar
ea
T88 C T88 PB
 
Figure 1. In vitro metabolism curves of TCBT 88 using rat hepatic microsomes of untreated (T88 
C) and phenobarbital pretreated (T88 PB) female rats. The microsomal incubations were 
performed in triplicate. 
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Table 2. In vitro metabolic rate constants (k; min-1.mg protein -1) of three TCBTs, using 
microsomal fractions of untreated or treated rats of both sex. The metabolic rate constants of 
untreated rats are mean values and their standard deviations (Std) based on three rats. The 
other metabolic rates are mean values(N=3) and standard deviations (Std) 
TCBT 87 TCBT 88 TCBT 94
Male rats
k Std k Std k Std
Untreated 0.015 0.001 0.018 0.005 0.044 0.001
BNF 0.029 0.001 0.029 0.022 0.074 0.002
CLO 0.015 0.010 0.013 0.009 0.051 0.012
DEX 0.120 0.005 0.107 0.007 0.351 0.001
ISO 0.049 0.003 0.035 0.004 0.322 0.012
PB 0.095 0.006 0.238 0.007 0.607 0.037
Female rats
k Std k Std k Std
Untreated 0.007 0.001 0.023 0.005 0.028 0.001
BNF 0.015 0.002 0.051 0.001 0.040 0.004
CLO 0.016 0.002 0.044 0.002 0.015 0.005
DEX 0.137 0.006 0.172 0.003 0.281 0.008
ISO 0.009 0.003 0.132 0.001 0.111 0.003
PB 0.081 0.001 0.292 0.004 0.809 0.076
 
A large variation in metabolic rate constants of the TCBTs was obtained by 
pretreating rats with the inducing agents (Table 2). The mean metabolic rate 
constants and standard deviation of untreated rats based on three rats were listed as 
well. TCBT 87 was metabolised at the lowest rate in microsomes of female rats. 
Metabolic rate constants of the PCBs (Table 3) were about two to fifty times 
lower relative to the metabolic rates of the TCBTs, based on microsomal fractions of 
untreated rats. The pretreatment of rats with the different inducers resulted in a wide 
range of metabolic rate constants of PCB 52, 77, 101 and 136.  
Table 3. In vitro metabolic rate constants for PCBs multiplied by 1000 (min-1.mg protein-1) using 
microsomal fractions of untreated or treated rats of both sex. The metabolic rate constants of 
untreated rats are mean values based on three rats. The other metabolic rate constants are 
mean values based on three determinations. Standard deviations are omitted for clarity reason.  
Treatment Sex di-ortho PCBs Mono-
ortho
PCB
Non-ortho PCBs
52 101 136 155 180 118 77 80 126
Untreated F 3.2 1.1 2.7 0.9 - - - 1.3 -
M 2.1 1.5 6.6 - - - - 1.7 -
β-naphthoflavone F - 1.3 1.4 1.0 0.9 - 12.2 - 1.4
M - 1.3 4.9 1.5 1.5 - 8.5 1.6 -
Clofibric acid F 4.3 - 1.3 - - - - - -
M 6.9 2.2 2.2 - - - - - -
Dexamethasone F - 2.1 25.4 0.9 2.3 - - - 1.2
M 7.1 2.1 31.4 0.9 - - - - -
Isosafrole F - - 12.1 - 1.9 - 6.3 - -
M - 24.3 74.9 1.4 1.3 - 17.9 3.0 1.1
Phenobarbital F 10.2 3.9 43.5 1.0 2.3 - - - -
M 28.7 25.1 54.2 2.1 1.5 - - - -
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Correlation analysis 
The results of the correlation analysis are presented in Table 4. Metabolism of the 
TCBTs was highly correlated with CYP 2B1 and 2B2 activity. Additionally, 
involvement of CYP2A1/2 or CYP3A1/2 was observed. The CYP2B1/2 correlated 
with the di-ortho PCBs 52 and 136. Additionally, CYP3A1 activity correlated with 
metabolism of PCB 136. Furthermore, PCB 155 correlated with CYP 2C11 activity. 
PCBs 77, 80, 126, and 180 did not correlate with any of CYP activities. 
Table 4. Spearman’s correlation coefficients (p<0.05) between k and CYP enzyme activities of 
TCBTs and PCBs. The combinations on which the correlations are based are tabulated (N). 
Statistically significant correlation coefficients are indicated in bold (p<0.05) or bold italic 
(p<0.01) 
CYP
2A1
2A2
3A1
3A2
(2A2)
2C11 2B1/2 2B1 1A1 1A2
N Testosterone metabolites AR activities
7α 15β 2α 16β Prod Erod Mrod
TCBT
87 18 0.46 0.52 0.20 0.76 0.50 -0.06 -0.35
88 18 0.28 0.72 0.57 0.69 0.54 0.22 -0.20
94 18 0.70 0.39 -0.08 0.75 0.70 0.15 -0.10
PCB
101 11 0.18 -0.47 -0.23 -0.28 -0.27 -0.19 0.39
126 3 0.50 0.50 0.50 -0.50 -0.50 0.50 0.50
180 7 -0.69 -0.25 -0.07 -0.40 0.40 0.49 0.29
80 4 -0.40 -0.20 -0.40 -0.40 -0.40 -0.27 -0.40
52 9 -0.37 -0.40 -0.33 0.76 0.68 -0.27 0.13
77 4 -0.40 -0.60 0.60 1.00 -0.40 -0.40 -0.40
136 18 -0.40 0.51 -0.25 0.64 0.50 -0.08 0.13
155 10  0.27 -0.15 0.76 0.28 -0.48 -0.76 -0.30
 
 
Characterisation inhibitors 
Figure 2 depicts the most specific inhibitor concentrations as well as their 
inhibition percentage. TAO inhibited the formation of 15α-, 6β-, 15β- and 2β-OHT 
metabolites, reflecting CYP 3A1/2 and 2A1/2 activity. ORP reduced 16β-OHT 
formation for 80 % and to a lesser extent the formation of 2α-OHT and 16α-OHT, 
reflecting CYP2B1 and 2B2, as well as CYP2C11 activity. Some overlap between the 
inhibitory effect of ORP and TAO was observed by the inhibition of 15α-OHT 
formation. In addition, MOP was not selective since it inhibited the formation of 
nearly all OHT metabolites except for 15β and 2β OHT. Therefore MOP was not a 
useful inhibitor for the purpose of this study.  
The inhibition of the metabolism of TCBTs and PCBs after co-induction with 
individual inhibitors is presented in Table 5. ORP, inhibits nearly 100 %, the 
metabolism of three TCBTs (P<0.05) and PCB 52, 101, 136 and 155, confirming the 
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involvement of CYP2B activity. TAO and ANF reduced the metabolic rates to a 
lesser degree. 
Table 5. Inhibition percentages for TCBT and PCBs as determined by the k values for the TCBTs 
and PCBs with and without inhibitor but corrected for the solvent (demineralised water or 
MeOH). (* statistically sigificant p<0.05) 
 TCBT 
87 
TCBT 
88 
TCBT9
4 
PCB 
52 
PCB 
77 
PCB 
101 
PCB 
136 
PCB 
155 
ORP 95.4* 99.3* 100* 100*  100* 96* 100* 
TAO 23* 1 26* 0  12.6 2.5 4.2 
ANF     39.7*    
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Figure 2. Effect of the inhibitors TAO, MOP and ORP at 30, 5 and 60 µM on the formation rate of 
OHT metabolites using microsomes from phenobarbital pretreated rats  
DISCUSSION 
Metabolic rate constants 
In vitro metabolism of TCBT or PCB congeners using rat hepatic microsomes can 
be described by first order kinetics. This is in agreement with other in vitro studies, 
which reported first order kinetics for PCBs and TCBTs using rat hepatocytes or 
hepatic microsomes (Kramer et al., 2000b; Mills et al., 1985; Vickers et al., 1986). In 
our study the disappearance of the parent compound was used as parameter to 
determine metabolic rate constants ( k ). To check the mass balance of the system the 
hardly metabolisable congener PCB 153 was added to the incubation (Muehlebach et 
al., 1991; Vickers et al., 1986). It has been demonstrated that microsomes from 
phenobarbital treated rats metabolised PCB 153 (Duignan et al., 1987) at rates below 
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the level of quantification of the metabolic rate constants in our study, which was 
estimated at 0.0004 min-1.mg protein-1. Thus, during the time interval of the in vitro 
assay it is not likely that metabolism of PCB 153 influences the outcome.  
The in vitro metabolic rate constants of the presently analysed PCBs were 
relatively low. This was expected because most of the congeners, such as PCB 52, 
101, 118 and 180, are specifically used as indicators for exposure to PCBs (Prachar et 
al., 1994) because of their known resistance toward metabolism. PCB 136, however, 
is known to be easily metabolised in vivo (Birnbaum, 1983) and in vitro (Schnellmann et 
al., 1983). In the present study the k values for PCBs were 2 to 50 times smaller than 
for the studied TCBTs. The more rapid metabolism of these TCBTs would imply 
that the PCBs in our study could accumulate to larger extent, than TCBTs.  
Correlation analysis 
Using correlation analysis the simultaneous contribution of multiple enzymes to 
the metabolism can be identified at once, which is an important advantage of this 
method (Parkinson, 1996). In the present study it was observed that CYP2B1/2, 
CYP2A1/2, and CYP3A1/2 metabolised the TCBTs. Furthermore, these enzymes 
appeared to play a role in the metabolism of the di-ortho PCB 52 and 136 also. No 
correlations between k of PCB 77 and EROD or MROD were found, due to small 
number of correlations (table 4), however, BNF and ISO increased the metabolic rate 
constants. These chemicals specifically induce CYP1A1 and CYP1A2 (Parkinson, 
1996). Inhibition by ANF showed that CYP1A2 is likely to play a role in the 
metabolism of this congener. 
The identified enzymes CYP2B1 and 2B2 occur in the liver, lung and in the small 
intestines. The lungs contain 50% more and the small intestines 30% more than the 
liver, which contains 90.4 pmol.mg-1protein (De Waziers et al., 1990). These results 
suggest that the TCBTs and the di-ortho PCBs could be metabolised by these tissues 
as well. CYP1A1 (De Waziers et al., 1990) and CYP3A1/2 (Debri et al., 1995; 
Gushchin et al., 1999) occur also in the small intestines suggesting that this tissue also 
contributes to the metabolism of the congeners. In general, exposure to PCBs occurs 
by oral ingestion. Thus, during the uptake from the GI tract CYP2B1/2, 1A1, 3A1/2 
could already metabolise the TCBTs or the PCBs, suggesting lower bioavailabilities. 
The involvement of CYP2B1/2 and CYP1A2 in the metabolism of the di-ortho 
substituted PCB 136 and the non-ortho substituted PCB 77, respectively, confirmed 
results obtained using purified CYP 2B1, CYP1A1, and CYP1A2 enzymes (Kaminsky 
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et al., 1981). CYP1A enzymes preferably metabolised non-ortho PCBs and CYP2B 
enzymes preferably metabolised di-ortho PCBs (Kaminsky et al., 1981).   
Since some CYPs show overlapping OHT formation, like CYP2A2 which forms 
7αOHT and 15βOHT (Funae and Imaoka, 1987; Halvorson et al., 1990), and mutual 
correlations between different OHT metabolites were observed, the interpretation of 
the results becomes complex. To confirm these correlations, CYP specific inhibitors 
are needed however, e.g. for CYP 2C11, 2A1 and 2A2 specific inhibitors were not 
available.  
In conclusion, metabolism of the TCBTs in the present study is clearly faster than 
that of the PCBs. This suggests that the TCBTs might accumulate less in mammals 
than the PCBs. In addition, the TCBTs are more comparable with di-ortho substituted 
PCBs than non-ortho PCBs based on the CYP enzymes involved in their metabolism. 
CYP2B1 and 2B2 play a major role in metabolism of di-ortho PCBs and TCBTs, while 
non-ortho PCBs seem to be metabolised by CYP1A enzymes.  
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CHAPTER 4 
METABOLIC RATE CONSTANTS OF UGILEC 141 ISOMERS 
AND POLYCHLORINATED BIPHENYL CONGENERS USING 
HUMAN HEPATIC MICROSOMES AND THE IDENTIFICATION 
OF INVOLVED CYTOCHROME P450 ENZYMES 
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ABSTRACT 
Ugilec 141, a technical mixture consisting of tetrachlorobenzyltoluenes (TCBTs), was 
introduced as a replacement of polychlorinated biphenyls (PCBs) in the early 1980s. 
Accumulation of these TCBTs in the environment has been reported. In the present study 
metabolic rate constants of TCBT 87, 88 and 94 and PCB 52, 77, 80, 101, 118, 126, 136, 
155 and 180 were determined by measuring the in vitro disappearance rates of parent 
compound using human liver microsomes (HLMs) from 17 donors. Additionally, HLMs were 
phenotyped for the major cytochrome P450 (CYP) activities: CYP1A2, CYP 3A4, CYP2C9, 
CYP2C19, CYP2B6, CYP2D6, CYP4A11. Correlation analysis of these data resulted in 
identification of the cytochrome P450 (CYP) enzymes involved in the metabolism of TCBT 
87, 88 and 94 and PCB 77, 101, and 136. The identification of CYPs was further 
substantiated using specific CYP inhibitors. It was concluded that CYP2B6 plays a major role 
in the metabolism of TCBTs and the di-ortho substituted PCBs followed by CYP3A4. The 
non-ortho PCB 77 was mainly metabolised by CYP1A2. Furthermore, large interindividual 
variation in metabolic rate constants for each congener was observed, with variation 
coefficients of 20 to 137 %. Comparison of the metabolic rates of the TCBTs and the PCBs 
showed that TCBTs were metabolised 10 to 300 times faster than PCBs. Therefore TCBTs 
are expected to accumulate less in human tissue than PCBs.
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INTRODUCTION 
Ugilec 141, was introduced on the European market in the early 1980s as an 
alternative for the use of polychlorinated biphenyls (PCBs). Ugilec 141 is a technical 
mixture of tetrachlorobenzyl toluenes (TCBTs) (Ehmann and Ballschmiter, 1989) and 
was used especially in hydraulic devices in mining industry. TCBTs are structurally 
and physico-chemically related to PCBs (VanHaelst, 1996). Shortly after their 
commercial introduction, TCBT levels up to 25 mg. kg-1 fish tissue were reported 
(Fuerst et al., 1987b), indicating that TCBTs were able to accumulate in the food 
chain. For these reasons the European Union prohibited the application of Ugilec 
141 in new machinery in 1994.  
PCBs have been detected in many environmental samples including human tissue 
with high concentrations in adipose tissue. Elimination of PCBs from human tissue is 
slow as indicated by long half-lives, ranging from 124 to 338 days or from 2.6 to 4.8 
years (Bruehler et al., 1988; Phillips et al., 1989). PCBs are predominantly eliminated 
from the organism by metabolism, which takes place primarily in the liver (Matthews 
and Dedrick, 1984). The rate-limiting step in the metabolism is a hydroxylation or 
oxidation reaction performed by cytochrome P450 enzymes (CYP) (Lutz et al., 1977; 
Matthews and Dedrick, 1984)). CYPs are also involved in the metabolism of TCBTs 
as was shown in vitro using rat hepatic microsomes (Kramer et al., 2000b).  
Cytochrome P450 is an enzyme complex consisting of different enzymes (for 
review see Wrighton and Stevens (1992). The amount and the types of CYPs present 
in the liver depend on the genetic make up of the organism and external factors like 
diet or drug use (Wrighton and Stevens, 1992). The CYP composition of an 
individual liver determines finally the metabolic rates of xenobiotics. Therefore, it is 
important to investigate which specific enzymes are involved in the metabolism of 
xenobiotics.  
The present study focussed on in vitro metabolic rate constants of TCBTs and 
PCBs by using human liver microsomes (HLMs). Three non-ortho, one mono-ortho 
and five di-ortho substituted PCBs were selected. Three TCBTs were chosen because 
theoretically these isomers could interact with the Ah-receptor (VanHaelst et al., 1997) 
and as a consequence, could cause PCB and dioxin-like toxicity or biological effects 
(Safe, 1990; Safe, 1994). Furthermore, 17 different HLM samples were available to 
determine the interindividual variation of the metabolic rate constants for these 
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chlorinated substances. Moreover, the enzymes involved in the metabolism of 
TCBTs and PCBs were identified by correlation analysis (Clarke, 1998; Parkinson, 
1996). To perform the correlation analysis, the individual HLMs were phenotyped by 
determining the catalytic activities of CYP1A2, CYP 3A4, CYP2C9, CYP2C19, 
CYP2B6, CYP2D6, CYP4A11, representing 60 to 80 % of the total cytochrome P450 
enzymes in the human liver (Clarke, 1998; Gonzalez, 1992). In order to confirm the 
results obtained from the correlation analysis CYP activities were selectively inhibited. 
MATERIALS AND METHODS 
Chemicals 
TCBT isomers 3,3’,4,4’-Cl4-2-Me- (TCBT 87), 3,3’4,4’-Cl4-5-Me- (TCBT 88), and 
3,3’,4’,5-Cl4-4-Me-tetrachlorobenzyltoluene (TCBT 94) with a purity of >95 % 
(DeLang et al., 1998) were kindly provided by Prof. L. Brandsma from the 
Department of Preparative Organic Synthesis of the Chemistry Faculty of Utrecht 
University. The isomers are numbered according to Ehmann and Ballschmiter (1989). 
PCB 2,2’,5,5’-TCB (PCB 52), 3,3’,4,4’-TCB (PCB 77), 3,3’,5,5’-TCB (PCB 80), 
2,2’,4,5,5’-PnCB (PCB 101), 2,3’,4,4’,5-PnCB (PCB 118), 3,3’,4,4’,5-PnCB (PCB 126), 
2,2’,3,3’,6,6’-HxCB (PCB 136), 2,2’,4,4’,5,5’-HxCB (PCB 153), 2,2’,4,4’,6,6’-HxCB 
(PCB 155), and 2,2’,3,4,4’,5,5’-HpCB (PCB 180) congeners were obtained from Dr 
Ehrenstorfer (Augsburg, Germany). Their purity was >98%. Analytical grade n-
hexane, acetone, methanol (MeOH), acetonitrile were obtained from J.T. Baker 
(Deventer, The Netherlands). Glucose-6-Phosphate (G6P), and glucose-6-phosphate 
dehydrogenase (G6PDH) were obtained from Boehringer (Mannheim, Germany). 
MgCl2, K2HPO4, and NaH2PO4 were obtained from Merck (Darmstadt, Germany). 
Lauric acid, bovine serum albumin, NADP, α-naphtoflavone (ANF), troleandomycin 
(TAO), caffeine, and testosterone, were obtained from Sigma (St. Louis, MO, USA). 
S-mephenytoine, nirvanol, and 4-OH-mephenytoine were purchased from Ultrafine 
chemicals (Manchester, UK). Orphenadrine (ORP) was obtained from Fluka AG 
(Buchs, Switserland). Tolbutamide was obtained from BUFA (Uitgeest, The 
Netherlands).  
Human livers 
Human liver tissue of 17 donors was obtained from redundant material after bi-
partitioning of livers procured from multi-organ donors. The human livers were 
handled as described before (Olinga et al., 1998). Consent from the legal authorities 
Chapter 4 
 38 
and from the families concerned was solicited for the explantation of organs for 
transplantation purposes. The set of HLMs consisted of 9 livers from males with ages 
ranging from 2 to 51 with an average of 26.5. Eight female livers were obtained from 
donors with ages ranging between 6 and 53, with an average of 29.5. Human liver 
microsomes were isolated and stored until used according to Bouwman et al. (1992). 
The protein content was determined according to Bradford (1976) using a calibration 
curve with bovine serum albumin as a standard.  
Phenotyping of  HLMs 
Specific CYP activities were determined in triplicate as specified in table 1 using 
HLMs.  
Table 1. Overview of experimental conditions for the phenotyping assays 
CYP Substrate 
(Concentration µM) 
Protein 
(mg/ml) 
Incubation time 
(min) 
Reference 
1A2 Caffeine 
(500) 
1.0 60 (Wolkers et al., 1996) 
2C9 Tolbutamide 
(400) 
1.0 60 (Zweers-Zeilmaker et al., 
1996) 
2C19,2B6 S-mephenytoine 
(800) 
0.3 60 (Chauret et al., 1997; 
Lasker et al., 1998) 
2D6 Dextromethorphan 
(500) 
1.0 60 (Dayer et al., 1989) 
4A11 Lauric acid 
(200) 
0.5 10 (Jansen and DeFluiter, 
1992) 
3A4 Testosterone 
(300) 
0.5 15 (Drenth et al., 2000; 
Purdon and Lehman-
McKeeman, 1997) 
HPLC Analysis 
The analysis of the extracts were performed using a HPLC system from 
Gynkotek with a P580HPG pump, a UVD170S UV detector or a Kontron SFM 25 
fluorescence detector, and Basic Marathon autosampler (Separations, H.I. Ambacht, 
The Netherlands). The samples of the testosterone, tolbutamide, and lauric acid 
incubation assays were analysed using a Chromsep C18 (200 * 3 mm ID, 5 µm 
particles) column preceded by a 10 mm guard column packed with the same material 
(Chrompack, Middelburg, The Netherlands). Dextromethorphan assay extracts were 
analysed using a Chrompack C18 Steel column (100 * 3 mm ID., 5 µm particles). S-
mephenytoine assay samples were analysed using a Phenomenex C18 (150*4.60 mm) 
column preceded with a 30 mm guard column of the same material. The injection 
volume for each sample was 20 µl.  
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The HPLC methods are described in the references listed in table 1. Some minor 
modifications were applied as mentioned below. Tolbutamide assay extracts were 
analysed using a gradient mobile phase consisting of initially 85:15 10 mM sodium 
acetate (pH=4.3) and acetonitrile changing to 50:50 in 15 minutes at a flow rate of  
2 ml/min. S-mephenytoine metabolites were analysed using a gradient mobile phase, 
consisting initially of 45% MeOH and 55% water and was brought in 20 min to 100% 
MeOH, at a flow rate of 1 ml per min.  
In vitro metabolic rate assay 
In vitro metabolic rate constants were determined according to Kramer et al. 
(2000b) and Boon et al. (1998). Incubations were performed in triplicate at 37 °C 
using 1 mg microsomal protein in 0.95 ml 0.05 M phosphate buffer (pH=7.4), with a 
mixture of TCBT 87, 88, and 94 or PCB 52, 77, 80, 101, 118, 126, 136, 155, and 180 
at concentrations of 50 ng/ml. PCB 153 at a concentration of 50 ng/ml was added as 
internal standard. The reaction was started by adding 50 µl of a NADPH-regenerating 
system consisting of 1 µmol NADP, 5 µmol G6P, 0.95 Units G6PDH, 3 µmol MgCl2. 
At each time point (t=0- 90 min.) 200 µl aliquots were pipetted in a 1 ml 
MeOH:buffer solution (85:15 v/v). The TCBTs were extracted with 4 ml n-hexane 
(recovery >90%). The PCBs were extracted twice with 3 ml hexane (recovery >90%). 
The organic phase was collected and 100 µl of a volume standard (1.5 mg/l PCB 157) 
was added. The n-hexane evaporated at room temperature to nearly dryness. Then 
the volume of each sample was adjusted to ca. 500 µl with hexane and subsequently 
analysed.  
In vitro assay metabolic rate assay with inhibitors 
Inhibition studies were performed in triplicate, using the inhibitors ORP, TAO 
and ANF (Guo et al., 1997; Chang et al. 1994; Newton et al., 1995). One mg HLM 11, 
because of its high metabolic activity toward the TCBT and PCB 136, was 
preincubated in 1 ml 0.05M phosphate buffer, with NADPH-regenerating system and 
500 µM ORP or 20µM TAO for 15 minutes. Then 5 µl of the TCBTs or PCB 136 
dissolved in acetone (10 ng/µl) was added to start the biotransformation reaction. 
PCB 77 was co-incubated with NADPH-regenerating system and 0.5 µM ANF using 
1 mg HLM 8 because of its metabolic high activity toward PCB 77. The parent 
compounds were extracted as previously described and subsequently analysed.The 
percentage inhibition was calculated according to equation 1 
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inhibition −=   eq. 1 
GC analysis 
The samples were analysed on a Carlo Erba Mega 5360 HRGC-63Ni-ECD 
equipped with a 30 m DB5 column (ID 0.32 mm, film thickness 0.25 µm). PCB and 
TCBT samples were analysed using splitless injection with the following temperature 
program: 2 min at 70 °C, 20 °C/min to 255 °C for 5 min, 30 °C/min to 280 for 4 
minutes. The injector temperature was set at 250 °C. Splitless dosing times were 30 
seconds preinjection and 99 seconds postinjection. The injection volume was 1 µl. 
Calculation metabolic rate constant 
Disappearance of parent compound relative to PCB 153 from the incubation 
mixture could be described by first order kinetics (eq. 2). 
Ak
dt
dA *−=    eq. 2 
where A is the relative amount of TCBT or PCB to PCB 153, t is time (min) and 
k is the metabolic rate constant. The ratio of the peak areas of TCBT or PCB to PCB 
were logarithmically transformed and subsequently submitted to linear regression in 
time. The slope represented the metabolic rate constant. Only statistically significant 
(p<0.05) k values were used in the correlation analysis. An estimate of the detection 
limit of the k was obtained by calculating the minimal decrease of the relative amount 
of the parent compound based on two time the standard deviation of the t=0 
samples after 90 minutes of incubation. This resulted in a lowest estimate of the 
metabolic rate constant 6*10-4 min-1.mg protein-1.  
Correlation analysis 
Spearman’s correlation coefficients (S) between the CYP enzyme activities and k 
values for TCBTs and PCBs were calculated using SPSS for Windows (SPSS Inc. 
Chicago, USA). Correlations were considered statistically significant when p<0.05.  
RESULTS 
HLMs have been phenotyped for specific CYP activities. The results are listed in 
Table 2.  
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Table 2. Mean CYP activities (pmol/min/mg protein), standard deviation and the range of 
activities (min-max) of 17 HLM samples 
Assay CYP Mean Std Min Max 
Tolbutamide-hydroxylase  CYP2C9 511 244 238 1154 
Testosterone-6β-hydroxylase  CYP3A4 4650 3957 412 13052 
Caffeine-N-demethylase  CYP1A2 41 26 6 86 
Lauric acid-12-hydroxylase  CYP4A11 870 308 374 1452 
Dextromethorphan-O-demethylase  CYP2D6 240 104 54 397 
Nirvanol formation CYP2B6 44 54 7 155 
s-Mephenytoine-4-hydroxylase  CYP2C19 335 66 254 538 
 
In vitro metabolism of the TCBTs by HLMs could be described by first order 
kinetics. The individual k values showed large interindividual variation, as indicated 
by the large variation coefficient (Table 3). The order of metabolic rate constants 
among the isomers is TCBT 94>TCBT 88>TCBT 87, which was statistically 
significant according to Wilcoxon sign test (p<0.05). 
Compared to TCBTs metabolic rate constants of the PCBs were 10 to 50-fold 
lower (Table 3 and 4). Not all HLM fractions were able to metabolise PCBs to a 
measurable degree (estimated limit of quantification k <0.0006 min-1).  
Table 3. Mean metabolic rate constant (k) of the TCBTs based on different human liver 
microsomes with their corresponding variation coefficient (VC) and the minimum and maximum 
value of k. N is the number of HLMs. 
TCBT N k (min-1.mg protein-1) VC(%) Min Max 
87 16 0.059 137 0.004 0.243 
88 17 0.094 75 0.014 0.208 
94 17 0.274 76 0.069 0.733 
 
Strong correlations were found between CYP2B6 activity and the metabolic rates 
of the TCBTs (Table 5). To a lesser extent, k values of TCBT 88 and 94 correlated 
with CYP3A4 activity. The correlation between the k values of the individual isomers 
was high (S>0.8, P<0.001), indicating that the metabolism was catalysed by 
comparable CYPs. In addition, it appeared that enzyme activities mutually correlated; 
6β-testosterone-hydroxylase correlated highly with nirvanol formation (S=0.72, 
p=0.001), with caffeine-N-demethylase (S=0.67, p=0.003), and with lauric acid-12-
hydroxylase (S=0.6, p=0.011). 
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Table 4. Mean metabolic rate constant (k) of the PCBs based on different human liver 
microsomes with their corresponding variation coefficient (VC) and the minimum and maximum 
value of k. N is the number of HLMs 
PCB N k (min-1.mg protein-1) VC(%) Min Max 
52 4 0.0068 79 0.0006 0.0133 
77 17 0.0054 58 0.0009 0.0088 
80 1 0.0011    
101 8 0.0010 40 0.0005 0.0012 
118 3 0.0028 121 0.0008 0.0067 
126 3 0.0014 20 0.0012 0.0017 
136 10 0.0017 82 0.0006 0.0045 
155 5 0.0035 68 0.0008 0.0040 
180 5 0.0012 52 0.0009 0.0023 
 
Table 5. Spearman’s correlation coefficients (S) between metabolic rate constants of TCBTs and 
CYP activities based on human liver microsomes. 
TCBT CYP3A4 CYP1A2 CYP2D6 CYP4A11 CYP2B6 CYP2C19 
87 0.45 0.23 0.30 0.28 0.87** 0.31 
88 0.60* 0.46 0.24 0.38 0.93** 0.46 
94 0.56* 0.45 0.37 0.35 0.85** 0.44 
*p<0.05, **p<0.001 
 
Metabolic rate constants of PCB 136 correlated statistically significantly with 
CYP2B6 and CYP3A4 activity (Table 6), while k values of PCB 77 correlated highly 
with CYP1A2 activity and to a lesser extent to CYP3A4 activity. For PCB 101 a 
correlation between k and CYP2C19 activity was observed. The statistically 
significant correlations of PCB 52, 118, 126, and 180 are based on a limited number 
of data and therefore considered of limited value.  
Table 6. Spearman’s correlation coefficients between k of PCBs and CYP activity 
PCB N CYP3A4  CYP1A2  CYP2D6  CYP4A11  CYP2B6  CYP2C19  
52 4 1.0* 0.00 0.20 -0.40 -0.60 1.0* 
77 17 0.63* 0.92*** 0.14 0.29 0.34 0.32 
80 1 - - - - - - 
101 8 0.46 0.68 0.08 0.48 0.48 0.79* 
118 3 0.50 -0.50 0.50 -0.50 -0.50 1.00* 
126 3 -1.0 0.50 -1.0* -0.50 -1.0* -0.50 
136 10 0.79** 0.33 0.006 0.006 0.94*** 0.27 
155 5 -0.56 -0.21 0.10 -0.21 0.67 0.21 
180 5 -0.70 -0.60 -0.60 0.90* -0.60 0.90* 
*p<0.05, **p<0.01 ***p<0.001 
 
Correlation analysis showed that CYP2B6, and CYP3A4 were the main enzymes 
involved in metabolism of the TCBTs and PCB 136, and CYP1A2 played a major 
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role in the metabolism of PCB 77. To confirm these observations, specific inhibitors 
were used to inhibit metabolism of the TCBTs or the PCBs. The results are presented 
in Table 7. 
Table 7. Percentage inhibition of metabolic rate constants of the TCBTs and the PCBs after co-
incubation with TAO, ORP or ANF (at 1 and 10 µM). The data represent the mean inhibition and 
the standard deviation based on three determinations.  
Inhibitor CYP TCBT87 TCBT88 TCBT94 PCB77 PCB136 
TAO 3A4 -18±9 -12±5 64±16*  96±23* 
ORP 2B6 97±7.4* 80±21* 79±11*  100±11* 
ANF (1 µM) 1A2    9±5  
ANF (10 µM) 1A2    85±9*  
*statistically significant (p<0.05) 
 
ORP inhibited the metabolism of the TCBTs and PCB 136 almost completely 
(Table 7). These results confirmed that CYP2B6 indeed played an important role in 
the metabolism of these chemicals. TAO, which is a CYP3A4 inhibitor, markedly 
reduced the metabolic rate constant of PCB 136 and, to a lesser extent, TCBT 94. 
The inhibitory effect of ANF on the metabolic rate constant of PCB 77 became 
statistically significant at 10 µM, confirming the involvement of CYP1A2 in its 
metabolism (Table 6). 
DISCUSSION 
The TCBTs were much more rapidly metabolised than the PCBs. These results 
agree with earlier results based on rat hepatic microsomes using the same TCBTs and 
PCBs (Kramer et al., 1999). Thus, humans also metabolise these TCBTs more easily 
than the PCBs. This suggests that TCBTs show a lower potential for accumulation in 
humans than PCBs.  
The main conclusion from the correlation analysis was the involvement of CYP 
2B6 in the metabolism of the three TCBTs and PCB 136. This was confirmed by the 
almost complete inhibition by ORP that inhibits CYP2B6 activity (Guo et al., 1997). 
It has been observed that at the used ORP concentration approximately 20% of 
CYP3A4 activity was inhibited as well (Guo et al., 1997). Additionally, involvement of 
CYP3A4 activity to the metabolism of PCB 136 and TCBT 94 was confirmed by the 
selective inhibitor TAO (Chang et al., 1994; Newton et al., 1995).  
The contribution of CYP2B6 to the metabolism agrees with the results of a 
similar study using rat hepatic microsomes in which enzymes of the same family 
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(CYP2B1 and 2B2) were responsible for the metabolism (Kramer et al., 1999). In our 
study metabolic rate constants of PCB 77 correlated highly with CYP1A2 activity. 
Inhibition by ANF, a selective inhibitor of CYP1A2 activity (Chang et al., 1994; 
Newton et al., 1995), confirmed this correlation. The presently obtained results agreed 
with studies on purified CYPs. CYP1A1 metabolised the planar non-ortho PCBs, like 
e.g. PCB 77 and CYP 2B1 metabolised ortho-substituted PCBs, like PCB 136 
(Kaminsky et al., 1981; Kennedy et al., 1981; Matsusue et al., 1996). Since metabolism 
of TCBTs correlates with CYP2B activity this suggests that these isomers resemble 
di-ortho PCBs, with respect to their structure. Consequently, this suggests that TCBTs 
have a bulky structure. This could imply that binding to the Ah-receptor, which 
requires planar compounds, is not very likely in contrast to what was suggested for 
these TCBTs (VanHaelst et al., 1997).  
The CYP activities of HLMs in our study, correspond with literature data 
(Chauret et al., 1997; Dirven et al., 1991; Eagling et al., 1998; Gorski et al., 1994). 
Therefore it can be anticipated that the HLMs in our study reflect hepatic enzyme 
activities of the general population. The mutual correlations suggest co-regulated 
which means that high enzymes activity of one CYP also implies high enzyme activity 
of the co-regulated one (Forrester et al., 1992; Shimada et al., 1994). In our study 
CYP3A4 consistently correlated with CYP2B6, which agrees with Shimada et al. 
(1994). 
In conclusion, HLMs metabolised the TCBTs faster than the examined PCBs. 
These results suggest that accumulation of TCBTs in humans can be expected to be 
substantially lower than for PCBs. Furthermore, strong indications were obtained that 
CYP 1A2, 2B6 and 3A4 play a role in metabolism of TCBTs and PCBs. Within 
seventeen HLMs, large interindividual variation in metabolic rate constants was 
demonstrated. .
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ABSTRACT 
Ugilec 141 is a technical mixture of tetrachlorobenzyltoluenes (TCBTs). It was 
introduced in the early 1980s as a replacement for polychlorinated biphenyls (PCBs). Based 
on physicochemical properties and accumulation in the environment, the use of this mixture 
was prohibited. To gain more insight in the toxicokinetics of these compounds in mammals, 
rats were exposed to a single intravenous bolus injection of a mixture of three TCBTs. At 
different time points after dosing the tissue and blood concentrations of the TCBTs were 
determined. The adipose tissue is the main storage compartment, followed by skin and 
muscle. The TCBTs were rapidly eliminated from the liver and the blood, with half lives 
ranging from 65 to 72 h. Additionally, the tissue concentration data for all three TCBTs 
were analysed using a Physiologically Based Pharmacokinetic (PB-PK) model. Sensitivity 
analysis illustrated that the elimination of the TCBTs was not influenced by metabolism 
only, but also by the blood flow through the liver. Furthermore, the metabolic rates derived 
from the model were compared to previously reported in vitro metabolic rate constants. 
The in vitro values for the TCBTs were only a factor 2 to 3 smaller than the in vivo 
metabolic rates, indicating the value of in vitro techniques for a priori parameterisation of 
PB-PK models.  
Chapter 5 
 46 
INTRODUCTION 
The technical mixture Ugilec 141 consists of tetrachlorobenzyltoluenes (TCBTs) 
isomers. It was developed in the early 1980s as a replacement for mixtures of 
polychlorobiphenyls (PCBs), especially in the mining industry. Similarities have been 
reported between TCBTs and PCBs with respect to physicochemical properties 
(VanHaelst, 1996), biochemical changes in mice (Murk et al., 1991) and accumulation 
in fish (Fuerst et al., 1987b; Wammes et al., 1997). Due to the unwanted presence of 
Ugilec 141 in the environment and biota, the European Union prohibited the 
application of Ugilec 141 in new systems in 1994.  
Presently, information of possible accumulation of TCBTs in mammals is limited. 
One study indicated that the mixture Ugilec 141 was eliminated faster from rat liver 
tissue than 2,2’,4,5’5-PnCB (Bouraly, 1989).  
Physiologically Based Pharmacokinetic (PB-PK) models have been used 
successfully to analyse the pharmacokinetic behaviour of lipophilic substances like 
PCBs and dioxins (Andersen et al., 1993; Kedderis et al., 1993; Lutz et al., 1977; Lutz et 
al., 1984). The parameters of such models may be obtained a priori, either from 
literature, in vitro studies, or by fitting the model to the experimental data or from in 
vivo experiments (Yang and Andersen, 1994). Extrapolation of in vitro metabolic rates 
resulted in good estimates for the in vivo metabolism of volatile and non-volatile 
organic chemicals (Carlile et al., 1998; Houston, 1994b; Houston and Carlile, 1997; 
Krishnan and Andersen, 1994), but lipophilic substances, like TCBTs have not been 
studied in this respect. 
The aim of the present study was to determine the kinetics of TCBTs and to 
determine the potential of these compounds to accumulate in mammals. Hence, rats 
were intravenously injected with a single bolus dose of a mixture of three TCBT 
isomers. The tissue concentrations were determined at various time points after 
dosing, and analysed using a PB-PK model. Furthermore, in vitro metabolic rate 
constants were compared to in vivo metabolic rate constants. 
MATERIALS AND METHODS 
TCBT isomers 3,3’,4,4’-Cl4-2-Me- (TCBT 87), 3,3’4,4’-Cl4-5-Me- (TCBT 88), and 
3,3’,4’,5-Cl4-4-Me-Tetrachlorobenzyltoluene (TCBT 94) were kindly provided by 
Prof. L. Brandsma, from the department of Preparative Organic Synthesis of the 
PB-PK for TCBTs in rats  
 47  
Chemistry Faculty of Utrecht University, The Netherlands. The isomers are 
numbered according to Ehmann and Ballschmiter (1989). The purity of the isomers is 
>95% (DeLang et al., 1998). 2,2’,4,4’,5,5’-HxCB (PCB 153) was obtained from Dr 
Ehrenstorfer (Augsburg, Germany). The purity was >98%. Analytical grade n-hexane 
and acetone were obtained from J. Baker (Deventer, the Netherlands). 
Animals 
Adult male CPB:uWU rats (250-300 g) obtained from the Central Animal 
Laboratory Utrecht University were acclimatised for 5 days. Rats were housed 
individually in Macrolon III cages with filter top. Animals were maintained on a 12-
hour light/dark cycle under conditions of constant temperature and humidity. The 
rats were provided with rodent chow and tap water ad libitum. After five days the rats 
were weighed and dosed intravenously with a mixture of: TCBT 87 (0.43 mg/kg), 
TCBT 88 (0.45 mg/kg), and TCBT 94 (0.48 mg/kg). The mixture was dissolved in a 
20% tween/water (v/v) solution (polyethylenesorbitanmonooleate, Sigma, St. Louis, 
MO, USA) and administered via the tail vein at a constant volume of 1 ml/kg.  
Animals were killed in groups of three over a period of 168 hours (t= 6, 10, 24, 
48, 96 and 168 h) after sedation with CO2 gas, which was followed by exsanguination 
by aorta punction. Blood was collected in glass tubes with EDTA as anticoagulant 
and stored at 4 °C until further use. About 1 to 4 g of liver, abdominal skin, 
abdominal adipose tissue, and muscle from the hind leg were collected. The tissues 
and organs were weighed and stored at -80°C until further use. Blood from the liver 
was removed by perfusing with saline. 
Extraction of  tissues  
The frozen tissues and organs (except for blood samples) were freeze dried for  
48 h. The dried samples were placed in a paper cartridge and spiked with 100 µl of 
PCB 153 (1.6 mg/l; internal standard) in n-hexane. Subsequently the samples were 
extracted with 80 ml n-hexane under reflux for 16 h (Bouraly, 1989). The recovery of 
the extraction was 90 ± 5.6 %. The extract was collected in pre-weighed flasks and 
the n-hexane was evaporated under nitrogen. The n-hexane extractable fat was then 
determined gravimetrically.  
Clean-up 
Glass columns (∅ 1 cm, 20 cm length) were filled with 4 grams Florisil (mesh 60-
200 µm) deactivated with 5% water (w/w) to remove the n-hexane extractable fat 
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(Bouraly and Millischer, 1989). The column was pre-eluted with 5 ml n-hexane before 
adding 1 ml of the tissue sample containing maximally 100 mg fat extract. The 
samples were eluted with 30 ml n-hexane. The recovery of the clean-up over the 
column was 70 ±3.7 %. The eluates were concentrated prior to gas chromatographic 
analysis to a volume of ca. 500 µl.  
Blood sample clean-up 
Blood was extracted using 2 ml acetone and 2 ml n-hexane per gram blood (Boer 
and Wester, 1993). Prior to the extraction PCB 153 (1.6 mg/l) was added as an 
internal standard. The mixture was shaken for 30 seconds and centrifuged for 1 
minute at 3000 rpm. The extraction was repeated three times. The organic phase was 
collected in pre-weighed vials and evaporated at room temperature under nitrogen. 
The n-hexane:acetone extractable fat content was determined gravimetrically. The 
recovery was 101 ±10 %. 
GC-analysis 
The extracts were analysed on a Carlo Erba Mega 5360 HR-GC-63Ni-Electron 
Capture Detector equipped with a 15 m DB5 column (ID 0.32 mm, film thickness 
0.25 µm). Samples were analysed using splitless injection according to the following 
temperature program. The analysis started at 70 °C, after 2 minutes temperature 
increased to 255 °C at 20°C/min temperature. After 5 min at 255 °C, temperature 
increased to 280 °C at a rate of 30 °C/min. After 4 minutes at 280 °C the analysis 
stopped. The injector temperature was set at 250 °C. Splitless closing times were 30 
seconds preinjection and 99 seconds postinjection. The injection volume was 2 µl. 
The peak areas of the different compounds were determined relative to the peak area 
of PCB 153. Calibration curves for each compound using the internal standard PCB 
153 (1.6 mg/l) were used to quantify the amount per sample. This amount was 
divided by the wet weight of the tissue or blood sample.  
Model description 
The general model structure (Fig. 1) was based on a model for PCBs (Lutz et al. 
1977; Lutz et al. 1984). 
The chemical uptake by the liver, and the remaining tissue, were modelled as a 
flow limited process. The tissue uptake by adipose tissue, muscle and skin was 
described by a diffusion limited process (Wang et al., 1997). It was assumed that 
TCBTs are eliminated by first-order metabolism in the liver only. 
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Figure 1. Physiologically based pharmacokinetic model for the kinetics of the TCBTs in rat. V, Q, 
C represent volume, blood flow and concentration of the different compartments, respectively. 
PAf, PAs, PAm represent the diffusional clearance. 
Table 1. Physiological parameter values 
Body weight (kg) 0.3 This study 
Cardiac output (l/h) 6.08 Brown et al. (1994) 
Fractional flow to tissues (% of cardiac output)   
Liver (Ql)  18.6 Brown et al. (1994) 
Fat (Qf) 7.0 Brown et al. (1994) 
Muscle (Qm) 27.8 Brown et al. (1994) 
Skin (Qs) 5.8 Brown et al. (1994) 
Remaining tissue (Qr) 40.8 Calculated 
Tissue volumes (% of body weight) for rat   
Liver (Vl) 4.7 This study 
Fat (Vf) 7.0 Brown et al. (1994) 
Skin (Vs) 19.0 Brown et al. (1994) 
Muscle (Vm) 40.4 Brown et al. (1994) 
Blood (Vb) 7.4 Brown et al. (1994) 
Remaining tissue (Vr) 13.5 This study 
Tissue blood volumes (% of tissue volume)   
Fat (Vbf) 5 Kedderis et al. (1993) 
Skin (Vbs) 2 Brown et al. (1994) 
Muscle (Vbm) 4 Brown et al. (1994) 
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Model parametrisation  
The physiological parameters are presented in Table 1. Tissue to blood partition 
coefficients (PC) were calculated according to Gallo et al. (1987). The PC for 
remaining tissue was set equal to the value for muscle.  
The diffusional clearance constants for the adipose tissue (PAfC), muscle 
(PAmC), skin (PAsC), as well as the metabolic rate constant (Kmet) were optimised to 
the tissue and blood concentration data. A normalised sensitivity analysis was 
performed to determine sensitivity of the model forecast to the parameters (Evans et 
al., 1994; Ploeger et al., 2000).  
Simulation software. The model equations (appendix A) were implemented in 
ACSL for Windows (version 11.4.1., MGA Software Inc. Concord. MA). Nelder-
Mead (simplex) algorithm was used to optimise the model parameters in ACSL math 
(version 1.2, MGA Software Inc.). 
RESULTS 
The highest tissue concentrations were found in the adipose tissue followed by 
skin, muscle, liver, and blood for all three TCBTs (Fig. 2). For blood and liver, a rapid 
initial decline in tissue concentration was followed by a slower terminal elimination 
phase (Fig. 2), which could be described by a first-order process. The estimated 
terminal half-lives from the blood were 71, 62 and 65 h for TCBT 87, 88 and 94, 
respectively. All tissue concentration data were described adequately with the PB-PK 
model (Fig. 2 A, B, C) using the optimised parameter values (Table 2). Slight 
overestimation of the skin and muscle concentration of TCBT 87 and TCBT 88 
between 6 and 48 hours after exposure was observed. 
TCBT 87 deviated from the other two TCBTs with respect to tissue distribution 
as reflected in the PCs, metabolic rate and diffusional clearance. The partitioning to 
the liver (Pl) of TCBT 87 was approximately seven times higher than for TCBT 88 
and 94. The relative distribution over the adipose tissue and the liver as indicated by 
the ratio Pf/Pl, appeared to depend on the isomer as well. The ratios were 12, 45 
and 36 for TCBT 87, 88 and 94, respectively. 
The metabolic rate constant of TCBT 87 was about 5 times lower than the 
metabolic rates of TCBT 88 and 94. The precision of the estimation of the metabolic 
rates, as indicated by the coefficient of variation (CV), ranged from 6-10 %, and was 
comparable among the isomers. The diffusional clearance constants for TCBT 87 in 
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each tissue tended to be higher than for the other two compounds. These estimates 
were less precise relative to the metabolic rate constants, for all three isomers, with 
CVs ranging from 0.5 to 35 %. 
Table 2. Parameter values: calculated partition coefficients (Px), fitted diffusional clearance 
constants and fitted metabolic rate constants after iv injection.  
 TCBT87 TCBT88 TCBT94 
Partition coefficients *) 
Pl (Liver) 25 3.4 3.5 
Pf (Fat) 300 152 125 
Ps (Skin) 126 65 29 
Pm (Muscle) 23 14 7 
Pr (Remaining tissue) 23 14 7 
Diffusional clearance constants (h-1) 
PAfC (Fat) 0.14 (0.36)++ 0.04 (7.50) 0.04 (0.50) 
PamC (Muscle) 0.06 (18.33) 0.02 (35.00) 0.03 (4.66) 
PAsC (Skin) 0.60 (16.66) 0.26 (0.77) 0.16 (18.75) 
Metabolic rate constants (h-1) 
Kmet 2.1 (9.5)++ 10.3(5.8) 9.4 (8.5) 
*) calculated as AUCtissue/AUCblood  
++ coefficient of variation (CV; %) 
 
In vitro metabolic rate constants, as previously determined in hepatic microsomes 
from male rat (Kramer et al., 2000b) were compared to in vivo metabolic rate constants 
(Table 3). The in vitro values were a factor 2 to 3 smaller than the metabolic rate 
constants, obtained after optimising the model to the in vivo data. Alternatively, 
optimising the diffusional clearance only, while fixing the metabolic rate to the in vitro 
values, overestimates systematically the tissue and blood concentrations (data not 
shown).  
Table 3. Comparison of in vitro (Kin vitro) and in vivo (Kmet) derived metabolic rate constants 
TCBT Kin vitro(h-1)* Kmet (h-1) Kmet/Kin vitro 
87 0.96 2.1 2.2 
88 3.78 10.3 3.3 
94 4.14 9.4 2.2 
from Kramer et al. (2000b) 
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Figure 2. Concentration of TCBT 87 (A), TCBT 88(B) and TCBT 94 (C) in whole blood, liver, 
adipose tissue, skin and muscle of the rat. The lines represent the optimised model outcome. 
The scatter represent mean values and standard deviation (N=3).  
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The sensitivity of the PB-PK model forecast to the parameters is depicted in 
figure 3 and 4. It appeared that the blood concentrations were most sensitive to the 
metabolic rate (Kmet) during the distribution phase (Fig. 3). In addition, liver blood 
flow (Ql) was also a major determinant of blood concentration. An increase in the 
flow through the adipose tissue resulted in a slight increase in the blood 
concentrations (Fig. 3). Figure 4 shows that Kmet and the perfusion rate of the liver 
played a major role in the model predictions of the total amount metabolised. The 
sensitivity of the model to the diffusional clearance and the flow through the fat was 
only marginal as indicated by the small normalised sensitivity coefficients. Similar 
results from the sensitivity analysis were obtained for TCBT 88 and 94 (results not 
shown). 
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Figure 3. Sensitivity of model predictions to the metabolic rate (Kmet), and the perfusion rates of 
the adipose tissue (qf) and the liver (ql). The normalised predicted change in the concentration 
of TCBT 87 in blood concentration upon a 1 % change in the parameter values is plotted against 
time. 
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Figure 4. Sensitivity of Kmet, PAfC, Qf and Ql on the total amount metabolised using the PB-PK 
models for TCBT 87. The normalised predicted change in the total amount metabolised upon a 1 
% change in the parameter values is plotted against time.  
DISCUSSION 
The present study showed that all three TCBTs reached the highest 
concentrations in the adipose tissue followed by skin, muscle, liver, and blood. This 
tissue distribution of TCBTs is comparable to that of PCBs and other lipophilic 
compounds in rat (Jordan and Feeley, 1999; Moir et al., 1996; VandenBerg et al., 
1994). Furthermore, the first-order elimination of the TCBTs from the liver has also 
been observed for PCBs (Heinrich Hirsch et al., 1997; Matthews and Dedrick, 1984; 
Ryan et al., 1993). This confirms, in a qualitative way, our initial assumption about the 
comparability of the kinetics of PCBs and TCBTs. The uptake of TCBTs by the 
adipose tissue, muscle, and skin was presently modelled as a diffusion limited process, 
similar to previously reported models for 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) and 2,3,7,8-tetrabromodibenzo-p-dioxin (Andersen et al., 1997; Kedderis et 
al., 1993; Wang et al., 1997). Initially, Lutz and co-workers (1977) used relatively low 
blood flows for adipose tissue and muscle, e.g. 2.2 ml/min/100 g adipose tissue while 
Brown and co-workers (1994) reported a range of 18 to 48 ml/min/100g. A 
reduction of the blood flow resembled the effect of a diffusion limitation, but is not 
fully in agreement with the physiology. The diffusional clearance constants of closely 
related chemicals like for TCDD and tetrabromodibenzo-p-dioxin ranged between 
0.08 and 0.1 for adipose tissue, for muscle between 0.03 and 0.05 and for skin 
between 0.015 and 0.09 (Andersen et al., 1997; Kedderis et al., 1993; Wang et al., 
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1997). These parameter values agree with our results, suggesting a similar distribution 
process for TCBTs and dioxins. 
Although the octanol to water partition coefficients of the TCBTs lie in the same 
range (Log Kow 7.3-7.4), large differences in partition coefficients between the 
individual isomers were presently observed. TCBT 87 appeared to have the largest 
PCs for all tissues and the lowest fat to liver concentration ratio. The partitioning of 
TCBT 87 to the liver is relatively high (Pl=25), compared to Pls used in PB-PK 
models for related compounds. These Pls ranged from 3 to 17 (Kedderis et al., 1993; 
Lutz et al., 1977; Tuey and Matthews, 1980). TCDD and related compounds, like 
some PCBs, are selectively retained by CYP1A2 in the liver, causing alterations in the 
fat to liver concentration ratios, comparable to that observed for TCBT 87 (Andersen 
et al., 1997; Andersen et al., 1993; DeVito et al., 1998; VandenBerg et al., 1994). This 
suggests that the differences in tissue partitioning among the TCBTs, could be 
explained by selective retention of TCBT 87 by CYP1A2 in the liver.  
TCBT 87 also differs from the other two isomers with respect to its metabolic 
rate. TCBT 87 was metabolised slower than TCBT 88 and TCBT 94. This agrees with 
the results of the in vitro study (Kramer et al., 2000b). The present study showed that 
in vitro metabolic rate constants were 2 to 3-fold lower than the in vivo metabolic rates. 
This could be explained by the possible contribution of other tissues to the 
metabolism in vivo, since the in vitro data were based on metabolism in the liver only. 
However, differences in binding characteristics between in vitro and in vivo may be 
more likely, as was demonstrated for various drugs by Obach (1997). In this study, 
the extrapolation of in vitro data from experiments with microsomal fractions was 
improved when the free fractions of the substrate in the in vitro system and in vivo 
were taken into account. Thus, the factor of two to three between in vitro and in vivo 
might reflect the differences in the free fraction. 
The direct insertion of these in vitro values in the PB-PK model resulted in an 
overestimation of the tissue concentrations. 
Sensitivity of the metabolic rate constant on the model predictions of the amount 
metabolised showed that this parameter played an important role during the 
distribution phase of the TCBTs. This observation was substantiated by the almost 
similar terminal half-lives of the TCBTs, while the in vivo metabolic rate constants of 
the TCBTs differed maximally by a factor of five (Table 3). The blood flow through 
the liver also contributed substantially to the elimination as indicated by the 
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normalised sensitivity coefficient (Fig. 3). These findings suggest that other processes 
than the metabolism become rate limiting during the terminal elimination phase, like 
e.g. redistribution from the adipose tissue.  
In summary, the in vivo kinetics of TCBTs were comparable to that of PCBs, with 
the highest tissue concentrations in the adipose tissue. Furthermore, it was 
demonstrated that the PB-PK model adequately described the tissue concentration 
data. This model showed that TCBT 87 was distinct from the other two TCBTs with 
respect to tissue partitioning and metabolic rates. Additionally, the model illustrated 
that during the distribution phase, metabolism played an important role in the 
elimination of the TCBTs, while during the terminal elimination phase possible other 
processes e.g. redistribution from the adipose tissue become rate limiting.  
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CHAPTER 6 
PHARMACOKINETICS AND ORAL BIOAVAILABILITY OF 
TETRACHLOROBENZYLTOLUENES AND 
POLYCHLORINATED BIPHENYLS IN RATS  
 
 
H.J. Kramer, H. Drenth, M.vandenBerg, W. Seinen, and J.DeJongh 
 
Submitted to Toxicological Sciences 
ABSTRACT 
Ugilec 141 is a technical mixture consisting of tetrachlorobenzyltoluenes (TCBTs). It 
was introduced in the 1980s as a replacement for polychlorinated biphenyls (PCBs). 
However, the TCBTs also accumulated in the environment. To determine the amount that 
enters the organism via ingestion of contaminated food, the oral bioavailability of TCBT 87, 
TCBT 88, TCBT 94 and PCB 77, PCB 101, and PCB 118 was measured in the present study. 
Rats were administered a mixture of these compounds by a single intravenous injection or 
a single oral dose. The calculated bioavailability for TCBT 88 and TCBT 94 was <20% and 
for TCBT 87 48%. The calculated bioavailability of the PCBs ranged from 60 to 100%. Two 
physiologically based pharmacokinetic (PB-PK) models, representing either uptake via the 
portal vein or via the lymphatic route were optimised to the oral tissue concentration data 
to estimate the fraction of the dose that was absorbed from the gastro-intestinal tract as 
well as the absorption rate constant. Both PB-PK models described the tissue concentration 
equally well. Modelling the uptake via the portal vein route resulted in slightly higher 
estimates of the fraction of the dose that was absorbed compared to that of the uptake via 
the lymphatic route. Additionally, an inverse correlation was observed between in vitro 
metabolic rates and calculated bioavailability. Thus, the low bioavailbilities of the TCBTs 
were suggested to be caused by first-pass elimination in the gastro-intestinal wall rather 
than by reduced absorption. In conclusion, the bioavailability of the TCBTs is lower than 
that of the PCBs. 
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INTRODUCTION 
The technical mixture Ugilec 141 consists of tetrachlorobenzyltoluenes (TCBTs). 
It was developed in the early 1980s to replace mixtures of polychlorobiphenyls 
(PCBs). PCBs were widely spread in the environment, accumulated in biota and 
caused biological and toxic effects (Safe, 1993; Safe, 1994). Ugilec 141 is similar to 
mixtures of PCBs, with respect to their physicochemical properties (VanHaelst, 
1996), accumulation in fish (Fuerst et al., 1987b), and induction of enzyme activities in 
mice (Murk et al., 1991). Due to these similarities with PCBs the use of TCBTs was 
prohibited in the European Union in 1994. 
Exposure of mammals, including humans, to PCBs and TCBTs occurs in general 
via oral ingestion of food contaminated with these compounds. Absorption studies 
with PCBs have reported uptake efficiencies between 66 and 96 % in rat (Fries et al., 
1989; Tanabe et al., 1981) and for humans between 27 and 88% (Schlummer et al., 
1998). These studies have also demonstrated that absorption of PCBs depends on 
molecular size, and number of chlorine atoms (Schlummer et al., 1998; Tanabe et al., 
1981). Furthermore, it has been suggested that first-pass elimination could occur for 
rapidly metabolisable PCBs, reducing their bioavailability (Lutz et al., 1977; Matthews 
and Anderson, 1975). 
After absorption from the gastro-intestinal tract (G.I-tract) in dog and sheep, 
trichlorinated PCBs (Log Kow 5-6) were taken up by the lymph (Busbee et al., 1985; 
Ziprin et al., 1980), whereas di-chlorinated PCBs (Log Kow 5-5.4) were transported via 
the portal vein (Busbee and Ziprin, 1994). This difference was suggested to be due to 
the lower lipophilicity of the di-chlorinated biphenyls. The difference between both 
transport routes is that uptake via the lymph avoids first-pass elimination by the liver. 
This implies higher bioavailabilities (Charman et al., 1997). 
Absorption efficiencies or first-pass elimination of TCBTs have not been studied 
yet. It has been shown that some TCBTs are rapidly metabolised in vitro using hepatic 
microsomes from rat and human (Kramer et al., 1999; Kramer et al., 2000a). 
Compared to 3,3’,4,4’-tetrachlorobiphenyl and 2,2’,3,3’,6,6’-hexachlorobiphenyl the in 
vitro metabolism of TCBTs was faster (Kramer et al., 2000a). This rapid in vitro 
metabolism suggested the possible occurrence of first-pass elimination of TCBTs in 
vivo after oral exposure. First-pass elimination reduces oral bioavailability, resulting in 
lower tissue levels.  
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In this paper the oral bioavailability of three TCBTs and three PCBs were 
determined after exposing rats orally and intravenously to a mixture of these 
compounds. A physiologically-based pharmacokinetic (PB-PK) model was used to 
describe the bioavailability and the absorption rate of the compounds either following 
uptake via the portal vein route or via the lymphatic route. 
MATERIALS AND METHODS 
TCBT isomers 3,3’,4,4’-Cl4-2-Me- (TCBT 87), 3,3’4,4’-Cl4-5-Me- (TCBT 88), and 
3,3’,4’,5-Cl4-4-Me-Tetrachlorobenzyltoluene (TCBT 94) were kindly provided by 
Prof. L. Brandsma, from the department of Preparative Organic Synthesis of the 
Chemistry faculty of Utrecht University. The isomers are numbered according to 
Ehmann and Ballschmiter (1989). The purity of the isomers is >95% (DeLang et al., 
1998). 3,3’,4,4’-TCB (PCB 77), 2,2’,4,5,5’-PnCB (PCB 101), 2,3’,4,4’,5-PnCB (PCB 
118), and 2,2’,4,4’,5,5’-HxCB (PCB 153) were obtained from Dr Ehrenstorfer 
(Augsburg, Germany). Their purity was >98%. Analytical grade n-hexane and acetone 
were obtained from J. Baker (Deventer, the Netherlands). 
Animals 
Adult male CPB:uWU rats (250-300 g) obtained from the Central Animal 
Laboratory Utrecht University were acclimatised for 5 days. Rats were housed 
individually in Macrolon III cages with filter top. Animals were maintained on a 12-hr 
light/dark cycle under conditions of constant temperature and humidity. The rats 
were provided with rodent chow and tap water ad libitum.  
After five days the rats were weighed and dosed orally or intravenously with a 
mixture of TCBTs and PCBs resulting in the following dose (mg/kg body weight): 
0.43 mg TCBT 87, 0.45 mg TCBT 88, 0.48 mg TCBT 94, 0.19 mg PCB 77, 0.20 mg 
PCB 101 and 0.08 mg PCB 118. The mixtures for the oral study were dissolved in 
acetone. For each rat a single pellet was spiked with the dosing mixture 48 hours 
prior to the dosing. Rats were fasted for 24 hours before ingesting the spiked pellet. 
After the oral dosing food was provided ad libitum. The iv dose was dissolved in 20% 
tween/water (v/v) (polyethylenesorbitanmonooleate, Sigma, St. Louis, MO, USA) 
and injected in the tail vein at a constant volume of 1 ml/kg. 
Animals from both the oral and iv study were killed in groups of three rats over a 
period of 168 hours (t= 6, 10, 24, 48, 96 and 168 h) after sedation with CO2 gas, 
which was followed by aorta exsanguination. Kidney, skin, adipose tissue and blood 
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were collected from orally exposed rat. Adipose tissue, skin, muscle, kidney, liver and 
blood were collected from iv exposed rat. Tissue and blood extraction, clean-up and 
analysis were performed as previously described in Chapter 5. The samples were 
dissolved in n-hexane and analysed using HRGC- 63Ni-ECD. 
Model description 
A PB-PK model, structurally similar to the model for TCBTs (Chapter 5), was 
applied to model the kinetics of the PCBs after intravenous dosing.  
This PB-PK model of Chapter 5 was extended with oral exposure (Fig. 1). The 
absorption of TCBT or PCB was described as first-order disappearance of the dose 
from the GI-tract (KA) into the liver, representing uptake via the portal vein route 
(eq. 1) or into the venous blood compartment (eq. 2), representing the uptake via the 
lymphatic route.  
FLDoseKALAlKmet
Pl
ClCAQl
dt
dAl ***)( +−−=    eq.1 
Al denotes the amount in the liver, t is time, Ql is the blood flow through the 
liver, CA is the concentration of the compound in the arterial blood, Cl is the 
concentration in the liver, Pl is the liver-blood partition coefficient, Kmet is the 
metabolic rate constant, KAL is the absorption rate constant from the GI tract via 
the portal vein, and FL is the fraction of the dose absorbed. 
CAQcDoseFSKASCvQv
dt
dAb **** −+=     eq.2 
Ab denotes the amount in the blood, t is time, Qv is the flow of the venous blood, 
Cv is the concentration in the venous blood, KAS is the absorption rate constant 
from the GI-tract to lymph, FS is the fraction of the dose that is absorbed, Qc is the 
cardiac output and CA is the concentration in the arterial blood. 
Model parameterisation 
Table 1 shows the physiological parameters. Tissue to blood partition coefficients 
(PCs) were calculated according to Gallo et al. (1987). Diffusional clearance constants 
(PAfC, PAmC, PAsC) and metabolic rate constants Kmet were optimised to the PCB 
tissue concentrations of the iv study. 
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Figure 1. Physiologically based pharmacokinetic model for the TCBTs and PCBs in rat following 
uptake by the liver or by the lymph 
 Table 1 Model parameters 
Body weight (kg) 0.3 This study 
Cardiac output (l/h) 6.08 Brown et al. (1994) 
Blood flow to tissues (% of cardiac output)   
Liver (Ql)  18.6 Brown et al. (1994) 
Fat (Qf) 7.0 Brown et al. (1994) 
Kidney (Qk) 14.0 Brown et al. (1994) 
Muscle (Qm) 27.8 Brown et al. (1994) 
Skin (Qs) 5.8 Brown et al. (1994) 
Remaining tissue (Qr) 26.8 Calculated 
Tissue volumes (% of body weight) for rat   
Liver (Vl) 4.7 this study 
Fat (Vf) 7 Brown et al. (1994) 
Kidney (Vk) 0.7 this study 
Skin (Vs) 19 Brown et al. (1994) 
Muscle (Vm) 40.4 Brown et al. (1994) 
Blood (Vb) 7.4 Brown et al. (1994) 
Remaining tissue (Vr) 13.5 This study 
Tissue blood volumes (% of tissue volume)    
Fat (Vbf) 5 Kedderis et al. (1993) 
Skin (Vbs) 2 Brown et al. (1994) 
Muscle (Vbm) 4 Brown et al. (1994) 
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The bioavailability (FL or FS) and absorption rate constant (KAL or KAS) were 
obtained by fitting the PB-PK models for uptake via the portal vein route (eq. 1) or 
via the lymphatic route (eq. 2) to the tissue concentrations of the oral study. 
The bioavailability (BA) was calculated according to eq. 3:. 
ivbloodskinadipose
oralbloodskinadipose
VbAUCVsAUCVfAUC
VbAUCVsAUCVfAUC
BA
)***(
)***(
++
++
=
  eq. 3 
where AUC is the area under the tissue concentration curve and V is the volume 
of the tissue (Table 1). 
Simulation software. The model equations were written in ACSL for Windows 
(version 11.4.1., MGA Software Inc. Concord. MA) and are presented in the 
Appendix. For optimisation of the model parameters Nelder-Mead (simplex) 
algorithm was used of ACSL math (version 1.2, MGA Software Inc.). 
RESULTS 
Oral bioavailability of  TCBTs 
After oral ingestion of a food pellet contaminated with a mixture or the TCBTs 
(Fig.2), the highest concentrations were observed in the adipose tissue followed by 
skin, kidney and blood. Large differences in tissue concentration among the TCBTs 
were observed, although the rats were administered almost equal doses. The highest 
concentration in the adipose tissue was approximately 15 µg/kg tissue for TCBT 94, 
while for TCBT 87 the highest concentration in this tissue was approximately 300 
µg/kg tissue (Fig. 2). Blood concentrations of TCBT 88 and 94 between 80 and 160 h 
after exposure, were close to the detection limit of 0.1 μg/kg. 
The tissue concentrations of adipose tissue, skin and kidney were adequately 
described by the PB-PK model (Chapter 5) for uptake via the portal vein (Fig. 2, 
Table 3). The model underestimated the blood concentration and the kidney 
concentration of TCBT 94 (Fig. 2). The model for uptake via the lymph resulted in 
very similar fits (data not shown). This is illustrated by the almost equal weighed 
residual sum of squares from the model fits of both uptake models (Table 2).  
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Table 2. Overall Weighed Residual Sum of Squares of the PB-PK model for uptake via the liver 
and via the lymph of three TCBTs.  
 TCBT87 TCBT88 TCBT94 
 Liver Lymph Liver  Lymph Liver Lymph 
Overall 142 142 4.22 4.25 13.94 13.93 
 PCB77 PCB101 PCB118 
 Liver Lymph Liver  Lymph Liver Lymph 
Overall 15.02 15.04 3.63 3.68 9.62 9.04 
 
The bioavailability (BA) of TCBT 87, 88 and 94 was 48, 20 and 6%, respectively 
(Table 3). The fraction of the dose that was absorbed as fitted by the lymphatic 
uptake model (FS) was comparable to the calculated BA. The fraction absorbed as 
fitted using the portal vein route was slightly higher compared to that absorbed via 
the lymphatic route. The absorption rate constants were independent of the uptake 
models. 
Table 3. Fitted absorption rate constants (KAS or KAL) and bioavailability (FS or FL) of the TCBTs 
by uptake via either the portal vein route (L) or via the lymphatic route (S) and the calculated 
oral bioavailability (BA). The values between brackets represent the estimated coefficient of 
variation.  
 TCBT 87 TCBT 88 TCBT 94 
Calculated oral bioavailability 
BA* 0.48 0.20 0.06 
Uptake via lymph 
KAS 1.45 (0.58) 0.55 (0.34) 0.57 (0.01) 
FS 0.42 (0.10) 0.12 (0.10) 0.04 (0.01) 
Uptake via portal vein 
KAL 1.84 (0.80) 0.55 (0.34) 0.58 (0.46) 
FL 0.69 (0.10) 0.18 (0.10) 0.06 (0.14) 
*BA was calculated according to eq. 3 
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Figure 2. Rat tissue concentrations of TCBT 87(A), TCBT 88(B), and TCBT 94(C) after a single 
oral dose as described by the PB-PK model for uptake of TCBTs via the portal vein. The lines 
represent the optimised model simulation, the scatter represents the mean values of three 
determinations with standard deviation. 
PB-PK model for the PCBs after intravenous dosing 
The tissue disposition of the PCBs after the intravenous injection was 
comparable to that after oral exposure (Figs. 3 and 4). The highest concentrations 
were observed in the adipose tissue, followed by the skin, muscle, kidney, liver, and 
blood. The PB-PK model of the PCBs described the iv data adequately (Fig 3, Table 
4).  
Significant differences in metabolic rate constants (Kmet) among the PCBs were 
observed (Table 4). The lowest Kmet was found for PCB 118. The Pf of PCB 118 was 
also the lowest compared to that of the other two PCBs. The diffusional clearance 
constants of each tissue were comparable among the three PCBs. No differences in 
the coefficients of variation were observed among the optimised parameter values. 
Oral bioavailability   
 65  
Table 4. Parameter values: calculated partition coefficients (Px), and fitted diffusional clearances 
(PAxC) and fitted metabolic rates (Kmet) after iv injection of rats with a mixture of PCBs using 
the PB-PK model 
 PCB77 PCB101 PCB118 
Partition coefficients *) 
Pl (Liver) 9 3 7 
Pf (Fat) 112 75 35 
Ps (Skin) 53 41 21 
Pm (Muscle) 16 12 6 
Pk (Kidney) 4 5 4 
Pr (Remaining tissue) 16 12 6 
Diffusional clearance constant (h-1) 
PafC (Fat) 0.05 (0.16)+ 0.06 (0.13) 0.05 (0.20) 
PamC (Muscle) 0.01 (0.20) 0.02 (0.20) 0.02 (0.25) 
PasC (Skin) 1.0 (0.20) 0.20 (0.20) 0.85 (0.01) 
Metabolic rate constant (h-1) 
Kmet 1.3 (0.03)+ 2.5 (0.12) 0.2 (0.05) 
*) calculated as AUCtissue/AUCblood 
+) the coefficient of variation (%) is  
Oral bioavailability of  the PCBs 
The optimised parameter values of the two oral PB-PK models of the PCBs 
representing portal vein and lymphatic uptake are presented in Table 5.  
Table 5. Fitted absorption rate constants (KAS or KAL) and bioavailability (FS or FL) of the PCBs 
by uptake via either the portal vein route (L) or by the lymphatic route (S) and the calculated 
oral bioavailability (BA). The values between brackets represent the estimated coefficient of 
variation.  
 PCB 77 PCB 101 PCB118 
Calculated oral bioavailbility 
BA* 0.60 0.75 1.21 
Uptake via the lymph 
KAS 0.41 (0.27) 0.27 (0.28) 0.25 (0.43) 
FS 0.42 (0.12) 0.75 (0.09) 1.0 (0.33) 
Uptake via the portal vein 
KAL 0.42 (0.28) 0.27 (0.29) 0.26 (0.44) 
FL 0.47 (0.11) 0.82 (0.09) 1.0 (0.35) 
*BA was calculated according to eq. 3 
The fraction of the dose absorbed via the portal vein route (FL) was only slightly 
higher for PCB 77 and 101 compared to the uptake via the lymph. The calculated 
bioavailability (BA) of PCB 77 was 20 % higher than the fraction of the dose 
absorbed as estimated via the lymphatic route. No differences were observed between 
the absorption rates for both uptake models. Figure 5 shows that the PB-PK model 
for portal vein uptake, adequately described the tissue concentration data. Modelling 
the uptake via the lymphatic route resulted in similar model fits (data not shown). 
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This is illustrated by the almost equal weighed residual sum of squares of the model 
fits via both uptake routes (Table 2). 
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Figure 3. Tissue concentrations of PCB 77 (A), PCB 101 (B) and PCB 118 (C) after a single iv 
dose in rat as described by the PB-PK model. The lines represent the model simulation and the 
scatter represents the mean values of three determinations with standard deviation.  
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Figure 4. Tissue concentrations of PCB 77 (A), PCB 101(B), and PCB 118 (C) in rat, after a single 
oral dose as described by the PB-PK model for uptake of TCBTs via the portal vein. The lines 
represent the optimised model simulation, the scatter represents the mean values of three 
determinations with standard deviation. 
DISCUSSION 
The pharmacokinetics, including the bioavailability (BA) of three TCBTs and 
three PCBs, have been studied, by comparing tissue concentrations after an 
intravenous dose and an oral dose. The bioavailablilities of 6 and 20% for TCBT 94 
and 88 respectively were low relative to TCBT 87 with a BA of 48%. The PCBs in 
our study showed a relatively high BA, ranging from 60 to 121%, which agreed with 
results for PCBs reported by Fries et al. (1989) and Tanabe et al. (1981). Thus, PCBs 
sharing similar lipophilicities, molecular size and almost the same degree of 
chlorination with TCBTs are efficiently absorbed over the GI-tract. Therefore it is 
anticipated that the low systemic oral biovailability of TCBTs is not likely to be 
caused by limited absorption. Thus, other factors must be identified to explain the 
presently observed differences in bioavailability between PCBs and TCBTs. 
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It appeared from the present study that modelling the uptake of the TCBTs and 
the PCBs via either the portal vein route or via the lymphatic route described the 
tissue concentration data equally well. Therefore, it was not possible to select the 
most appropriate model for the distribution of these chemicals after oral absorption. 
From a physiological point of view, the difference between FL and FS is the fraction 
of the dose that is metabolised during the first passage of the liver. Thus, in the case 
of high first-pass metabolism a larger fraction of the dose could be absorbed via the 
portal vein route (FL) relative to the lymphatic route (FS) to obtain similar blood and 
tissue concentrations. This would result in a large difference between FL and FS. In 
our study FL was only slightly larger than FS, indicating that first-pass elimination in 
the liver, is not very important. Hence, the most likely explanation would be 
metabolism by either the microflora in the G.I-tract, or by enzymes in the gut wall 
during the absorption phase. 
When examining the bioavailability of the TCBTs and the PCBs as a function of 
their in vitro metabolic rate constants (Kramer et al., 2000b), an inverse relation is 
observed i.e. the higher the in vitro metabolic rate constant, the lower the oral 
bioavailability in vivo (Fig. 5). These observations strongly suggest that these 
compounds could be degraded before reaching the systemic circulation. 
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Figure 5. Relation between the calculated bioavailability and the in vitro metabolic rates from rat 
hepatic microsomes of the three TCBTs and the three PCBs 
 
Degradation of TCBTs or PCBs by microflora has not been reported previously. 
Only for hydroxylated PCBs this type of degradation has been observed (Bergman et 
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al., 1982; Gustafsson et al., 1981). Due to the limited data with respect to degradation 
of the PCBs and the TCBTs it was assumed that the contribution of possible 
degradation by the microflora was negligible. Thus, metabolism in the gut wall is the 
most probable explanation to explain the relatively low BAs for the three TCBTs.  
Metabolism in the gut wall is likely to occur since the enterocytes contain 
cytochrome 2B1 and 2B2 that are involved in the metabolism of the TCBTs in rat 
(Chapter 3). These enzymes occur in the intestines at 1.3 times their amount in the 
liver. CYP1A1 and 1A2 are involved in metabolism of PCB 77, which also occur in 
the small intestine and the liver, respectively (De Waziers et al., 1990). However, the 
contribution of other extrahepatic tissue, like lungs, can not be excluded.  
In conclusion, it was observed that the three TCBTs and the three PCBs were 
rapidly absorbed from the GI-tract. Although the present results were not conclusive 
about the transport of the chemicals via either the portal vein or the lymphatic route, 
the low bioavailability of the TCBTs could be explained by first-pass elimination in 
the gut wall. The low bioavailability of the TCBTs implies that the accumulation after 
oral ingestion will be lower than for the structurally related PCBs.  
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CHAPTER 7 
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF 
TCBTS IN HUMANS, USING IN VITRO METABOLIC RATE 
CONSTANTS 
 
 
H.J. Kramer, M.J. Zeilmaker, J.C.H. VanEijkeren, M. VandenBerg, and W. Seinen 
 
ABSTRACT 
Ugilec 141, a technical mixture consisting of tetrachlorobenzyltoluenes (TCBTs), was 
introduced on the European market in the early 1980s as a replacement for PCBs in 
hydraulic devices in the mining industry. From these systems TCBTs leaked into the 
environment and accumulated in fish. Since TCBTs are physicochemically related to the 
PCBs it was assumed that environmental problems would arise for TCBTs similar to that 
caused by PCBs, like food chain accumulation.  
To estimate if humans could accumulate these TCBTs via their food like PCBs, a PB-PK 
model for TCBTs in rat was adjusted to the human situation. In vitro metabolic rate 
constants from human liver microsomes were extrapolated to in vivo values, taking into 
account the free fraction of the substrate and the specific intrinsic clearance. To compare 
the possible tissue levels of TCBTs with those of PCBs, single and multiple dose simulations 
were performed, assuming a daily dose of 89 ng/kg. This is an estimate of the average 
daily intake of total PCBs in the European Union. Simulated steady state levels of TCBTs 
were approximately 100 to 1000 times lower than PCB levels observed in human tissue. 
The estimated half-lives of the TCBTs ranged from 26 to 111 days. Based on the model 
estimations it was concluded that the TCBTs accumulate to much lesser extent in human 
tissue than PCBs. 
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INTRODUCTION 
Ugilec 141 is a technical mixture consisting of tetrachlorobenzyltoluenes 
(TCBTs), which was used in hydraulic devices in mining industry because of its 
chemical stability. This highly lipophilic mixture was developed as a substitute for 
polychlorinated biphenyls (PCBs). PCBs are still ubiquitously present in the 
environment, and accumulate in the food chain, 30 years after the ban on their use. In 
top predators like e.g. humans high levels of PCBs have been measured, especially in 
the adipose tissue (Bachour et al., 1998; Patterson et al., 1994).  
Physicochemically the TCBTs are related to the PCBs (VanHaelst, 1996), and also 
accumulate in the environment, including fish (Fuerst et al., 1987b). This implies that 
humans could possibly accumulate these chemicals via consumption of fish. To 
elucidate whether this accumulation could occur, insight in the kinetics of these 
compounds is required.  
Three isomers (Fig. 1) were supposedly ligands for the Ah-receptor based on 
geometric considerations (VanHaelst et al., 1997). Interaction with this receptor is 
related to dioxin and PCB like toxicity. Thus, these three TCBTs could possibly cause 
dioxin-like toxicity. 
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
8787 9488
 
Figure 1. Chemical structure of three TCBTs. Numbering according to Ehmann and Ballschmiter 
(1989) 
The pharmacokinetics of these three TCBTs in rats have been studied and 
described by a physiologically based pharmacokinetic (PB-PK) model (Chapter 5). 
The advantage of PB-PK models is that they can be scaled to e.g. other species like 
human by adjusting tissue volumes and blood flows (Krishnan and Andersen, 1994) 
and using either allometry or in vitro metabolic rate constants to scale metabolism to 
the relevant species. It appeared that in vitro metabolic rate constants in rat hepatic 
microsomes, lie in the same order of magnitude as the in vivo values, indicating the 
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value of in vitro methods to determine metabolism for PB-PK modelling (Chapter 5). 
Since in vitro metabolic rate constants in human liver were already determined 
(Chapter 4), these values were scaled to the in vivo situation, using the specific intrinsic 
clearance and the free fraction (Houston et al., 1994b; Obach, 1997). 
The aim of the present study was to elucidate whether TCBTs would accumulate 
to similar levels as PCBs at similar exposure levels. Hence, the available 
pharmacokinetic data on the TCBTs have been integrated in a PB-PK model for 
humans. With this model tissue concentrations have been estimated after a single 
dose and multiple doses using the total daily PCB exposure that has been estimated 
by Duarte Davidson and Jones (1994), because dietary levels of TCBTs have not 
been reported, except for fish. The simulated tissue levels of the three TCBTs were 
compared to PCB concentrations that have been analysed in human tissue (Juan et al., 
2000; Petreas et al., 2000).  
MATERIALS AND METHODS 
The physiologically based pharmacokinetic model for TCBTs in the rat (Chapter 
5) was scaled to estimate the pharmacokinetics in humans. Hence the tissue and 
organ volumes, blood flows and cardiac output were adjusted to a human adult male 
of 70 kg (Table 1). The model simulations were performed using ACSL for windows 
(version 11.4.1. MGA Software Inc. Concord. MA) 
It has been demonstrated that tissue to blood partitioning in rat is lower than in 
humans for compounds with Log Kow ranging from 1 to 4 (DeJongh, 1997). 
Compounds with a Log Kow of 4 or more have almost equal partition coefficients 
(PCs) in both of these species. As TCBTs have a Log Kow of about 7, it was assumed 
that the PCs for TCBTs between rats and humans are comparable (Table 2). 
Furthermore the diffusional clearance constants and the absorption rates from the 
PB-PK model of TCBTs in rats were applied directly (Table 2).  
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Table 1. Physiological parameters  
Body weight (kg) 70  
Cardiac output (l/h) 342  (Brown et al., 1994) 
Blood flow through tissue (% of cardiac output)   
Liver 22.7 (Brown et al., 1994) 
Skin 5.8 (Brown et al., 1994) 
Muscle 19.1 (Brown et al., 1994) 
Adipose tissue 5.2 (Brown et al., 1994) 
Remaining tissue 47.2 This study 
Tissue volumes (% of body weight)   
Liver 2.6 (Brown et al., 1994) 
Skin 3.7 (Brown et al., 1994) 
Muscle 40.0 (Brown et al., 1994) 
Adipose tissue 21.4 (Brown et al., 1994) 
Blood 7.9 (Brown et al., 1994) 
Remaining tissue 15.3 This study 
Tissue blood volume (% of tissue)   
Adipose tissue 5 (Kedderis et al., 1993) 
Skin 2 (Brown et al., 1994) 
Muscle 4 (Brown et al., 1994) 
 
Table 2 Partition coefficients of three TCBTs for different tissues and diffusional clearances used 
in the PB-PK model for TCBTs in humans, obtained from PB-PK model of TCBTs in rats. 
 TCBT87 TCBT88 TCBT94 
Partition coefficients 
Pl (Liver) 25 3.4 3.5 
Pf (Fat) 300 152 125 
Ps (Skin) 126 65 29 
Pm (Muscle) 23 14 7 
Pr (Remaining tissue) 23 14 7 
Diffusional clearance constants (h-1) 
PAfC (Fat) 0.14 0.04 0.04 
PamC (Muscle) 0.06 0.02 0.03 
PasC (Skin) 0.60 0.26 0.16 
Absorption rate constants (h-1) 
Ka 1.84 0.55 0.58 
Bioavailability (%) 
BA 48 20 6 
 
The in vitro metabolic rates using human liver microsomes were determined by 
measuring the disappearance of the parent compound (Kramer et al., 2000b). This 
was modelled according to first order kinetics: 
0( ) exp( )vitroA t A k t= −    eq. 1 
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where A represents the amount at time t and A0 represents the amount substrate 
at t=0 and kvitro represents the metabolic rate constant. In eq. 1 it is assumed that the 
time scale for diffusion is much smaller than the time scale for metabolism, which 
allows for a one-compartment modelling approach. 
According to VanEijkeren (2000) kvitro may be expressed as a function of a 
number of experimental parameters and some intrinsic hepatic properties: 
,
/ 1 / /
m m sm m
vitro
m m i i m i i m
f CLf CLk
V f f V f f V V
= =
+ ⋅ + ⋅
  eq. 2 
 
where mCL  is the intrinsic clearance of the microsomes, and 
, /m s m mCL CL V=  is the specific intrinsic clearance i.e. the actual metabolic rate 
by the enzyme, mf  is the compound’s free fraction in the microsomes, if  is the 
compounds free fraction in the incubation fluid, mV  is microsomal volume in 
the incubations tested and iV  is the volume of the incubation fluid (note that 
the sum of mV  and iV equals the total volume of the in vitro system (Vtotal) in 
which metabolism is measured).  
,m sCL  and mf are the parameters of interest. They were estimated by fitting 
eq. 2 to kvitro data, which were obtained by varying the volume of the microsomal 
fraction mV , while holding the total volume of the in vitro system constant (Fig. 
2). Furthermore, eq. 2 was fitted to the kvitro data assuming if  to be 1 and Vi was 
substituted by Vi = Vtotal-Vm. 
In the PB-PK model metabolism in the liver is modelled as: 
AlKmet
Pl
ClCAQl
dt
dAl *)( −−=     eq.3 
where Al is the amount in the liver, Ql is the blood flow, CA is the arterial blood 
concentration, Cl is the concentration in the liver, Pl is the liver to blood partition 
coefficient, and Kmet is the metabolic rate in vivo. For the in vitro to in vivo 
extrapolation, it was assumed that, in analogy to the in vitro system described above, in 
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vivo metabolism occurs by microsomes floating around in an “incubation” volume, i.e. 
the liver. This assumption allows a direct extrapolation of eq. 2 to the liver in vivo:  
lmnnm
smm
VVff
CLf
Kmet
,
,
/*/1
*
+
=
    eq.4 
where Vn is the volume of the non microsomal fraction and Vm,l is the 
microsomal fraction of the complete liver, which is 45 mg per gram (Obach, 
1997), fn is the free fraction in the non microsomal fraction of the liver that is the 
only unknown parameter. Assuming that fn is 1 for highly lipophilic substances 
like the TCBTs, then an upper limit of the Kmet could be estimated (see Table 3): 
,
,
*
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Figure 2. Effect of microsomal protein concentration on the metabolic rate constants ( kvitro) 
determined according to Kramer et al. (2000b) using human liver microsomes. The incubations 
were performed in 1 ml with a variable microsomal fraction. CLm,s and fm were obtained by fitting 
eq. 2 to the in vitro metabolic rate constants. Each data point in the plot represents the mean 
value of three determinations. 
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Table 3 Estimated specific intrinsic clearance (CLm.s), the free fraction in the human liver 
microsomes of TCBTs (fm) and the estimate in vivo metabolic rate constant (Kmet), calculated 
according to eq. 5 
TCBT CLm,s (min-1) fm Kmet (h-1) 
87 16.8 0.0025 2.51 
88 41.7 0.0024 6.05 
94 181 0.0015 16.4 
 
In chapter 6 it appeared that, on the basis of the available data, no 
distinction could be made between uptake via the liver or the lymphatic uptake 
route. Thus, in the present human model, the TCBTs entered the liver assuming 
transport via the portal vein. 
The low bioavailability of the TCBTs in the rat has been suggested to be due 
to first-pass elimination in the gut wall (Chapter 6) by metabolism of TCBTs by 
CYP2B1, 2B2 and 3A1(Chapter 3). In human liver microsomes CYP2B6 and 
CYP3A4 are involved in metabolism of the TCBTs (Chapter 4), which are also 
expressed in human intestines (Gervot et al., 1999; Zhang et al., 1999). This 
suggests also first-pass elimination in humans, resulting in lower bioavailabilities. 
It was anticipated that the first pass elimination would compare to that in the rat 
(Table 2). 
The model performed single dose and multiple dose simulations. During the 
exposure period it was assumed that the body composition did not change. 
Furthermore, the multiple dose model assumed daily dosing of 6.2 µg (= 89 
ng/kg/d) based on a mean daily intake of total PCBs in Germany, Finland and 
the United Kingdom (Duarte Davidson and Jones, 1994) for a male adult of 70 
kg.  
RESULTS 
Single dose 
The tissue distribution and concentrations of all three TCBTs in humans after 
simulating a single oral dose were comparable (Fig. 3). An initial rapid decline in the 
TCBT concentration in the liver, blood and the remaining tissue was observed 
followed by a slower terminal elimination rate. The skin tissue reached the highest 
tissue concentration within a few hours followed by a rapid decrease and finally 
paralleled the terminal elimination rate of the blood and the liver (Fig. 3). The muscle 
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concentration decreased at a rather constant rate followed by the terminal elimination 
rate. TCBT 88 did not reach this rate after 2000 hours, while the other two did (Fig. 
3). Furthermore very slow elimination of all three TCBTs from the adipose tissue was 
observed (Fig. 3). 
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Figure 3 Tissue distribution in humans after a single oral dose of 89 ng/kg TCBT 87 (A), TCBT 88 
(B) or TCBT 94 (C) as simulated using the PB-PK model for humans 
 
Multiple doses 
Steady state of the TCBTs in blood was reached within 10 days (Fig. 4A) 
similar to the skin, liver and muscle (data not shown), while steady state in the 
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adipose tissue was reached at least after 300 dosages (Fig.4B) for TCBT 94. 
TCBT 87 and 88 achieved steady state after approximately 500 and 800 days, 
respectively (data not shown). The concentrations in the adipose tissue under 
steady state conditions of TCBT 94, 88 and 87 were 0.003, 0.060 and 0.142 
µg/kg adipose tissue, respectively. When dosing stopped after 300 days, the 
initial elimination rate from blood was high followed by a slower terminal 
elimination (Fig. 4A). Elimination from the adipose tissue paralleled the terminal 
elimination rate from the blood (Fig. 4B). The other tissues were comparable to 
the blood (results not shown). The terminal half-lives from the blood were 59, 
111 and 26 days for TCBT 87, 88 and 94, respectively. 
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Figure 4. Human blood (A) and adipose tissue (B) concentrations after 300 daily oral doses of 89 
ng/kg of TCBT 87, TCBT 88 and TCBT 94 according to the PB-PK model for TCBTs in humans.  
DISCUSSION 
The pharmacokinetics of TCBTs in humans were estimated by adjusting the PB-
PK model for TCBTs in the rat to the human physiology, with respect to blood flows 
tissue volumes and metabolism. The factor between the in vitro and in vivo metabolic 
rate constants in the rats was explained in terms of free fractions, specific intrinsic 
clearance and volumes as proposed by VanEijkeren (2000), Obach (1997) and 
Houston et al. (1994b). In the present study, these terms were quantified and used in 
the extrapolation to the in vivo situation, assuming a free fraction of 1 in the non-
microsomal fraction (fn) of the liver (eq.5). Table 4 shows, that under this assumption, 
the upper limit of the extrapolated in vitro metabolic rate constants from rat hepatic 
Chapter 7 
 80 
microsomes were a factor 3 to 10 lower than Kmodel, representing the in vivo metabolic 
rate as obtained by fitting the PB-PK model to the tissue concentration data (Chapter 
5). This factor agrees with Houston and Carlile (1997), who found an average 
difference between microsomal and in vivo clearance of a factor of approximately 5 
for various drugs like diazepam, warfarin, and tolbutamide. 
It appeared that, assuming fn is 1, provides a reasonable upper estimate of the in 
vivo metabolism in rats (eq. 5) that is approximately one order of magnitude lower 
than the apparent in vivo metabolism (Kmodel; Table 4). Since no differences were seen 
between rat, human and other species with respect to free fractions in the 
microsomes (Obach, 1997), this assumption was also considered appropriate for the 
human hepatic microsomes. This would also provide an underestimate of the in vivo 
metabolism in humans. As a consequence, inserting this underestimate of the hepatic 
metabolic rate constant in the PB-PK model would overestimate tissue levels. 
Table 4. Estimates of the free fraction of TCBT 87 and 94 in the microsomes (fm) and the 
metabolic rates of the enzyme (CLm,s) and the estimated Kmet in the rat using eq. 5. Kmodel 
represents the metabolic rate constant used in the PB-PK model for TCBTs in the rat  
TCBT# CLm,s (min-1)+ fm+ Kmet (h-1) Kmodel (h-1)* 
87 1.20 0.0036 0.26 2.1 
94 13.7 0.0039 3.19 9.4 
* Chapter 5 
+CLm,s and fm in rat hepatic microsomes were obtained by fitting metabolic rate constants that were 
determined by increasing the microsomal fraction in the incubation (similar to Fig. 2) 
# TCBT 88 no data available 
 
One explanation for the difference between in vitro and in vivo values could be 
attributed partly to the contribution of extrahepatic clearance since the in vitro 
metabolic rates were based on the liver enzymes only. The enzymes CYP2B6 and 
CYP3A4 that metabolise the TCBTs (Chapter 4) are also detected in human lungs 
and intestines (De Waziers et al., 1990). Thus it is likely that these tissues also 
contribute to the metabolism.  
After approximately 300 to 800 daily dosages, the TCBTs reached steady state 
concentrations in the adipose tissue, which was the highest for TCBT 87 with 0.14 
µg/kg. The accompanying steady state level in the blood was 0.07 ng /kg blood. In 
blood of five male adult volunteers from the United Kingdom assuming steady state, 
the levels of the very persistent PCBs 138, 153 and 180 ranged between 5 and 27 
ng/g lipid, while levels of other PCBs were approximately 5 ng/g lipid (Juan et al., 
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2000). Since the lipid fraction of human blood is approximately 0.5%, this implies 
levels of 25 to 135 ng/kg blood, which is approximately 300 to 2000 times higher 
than the model estimates for the TCBT blood concentration. Thus, the TCBTs have 
a two to three orders of magnitude lower potential to accumulate than the most 
persistent PCBs. This is due to the more rapid elimination of the TCBTs as indicated 
by the shorter terminal half-lives (26 to 111 days) compared to those of the PCBs 
which ranged between 2 to 6 years (Shirai and Kissel, 1996).  
The bioavailability in humans was assumed to be analogous to that in the rat 
(Table 2) ranging from 6 to 48 %. Modelling the tissue concentrations, assuming 100 
% bioavailability, increased the adipose tissue levels with a factor of approximately 2, 
5, and 20, respectively, to 0.29 µg/kg for TCBT 87, and for TCBT 88 and TCBT 94 
these levels would reach approximately 0.28 µg/kg and 0.05 µg/kg, respectively. 
Even these estimated levels are 30 to 2000 fold lower compared to PCB 
concentrations in adipose tissue of adult American women which ranged between 11 
µg/kg and 110 µg/kg for individual congeners (Petreas et al., 2000). 
The steady state levels in the adipose tissue were higher than the dose (89 
ng/kg/day). Expressing the tissue concentration at steady state relative to the dose 
provides a measure for the accumulation. Assuming 100 % bioavailability this would 
imply an accumulation factor of 3, for TCBT 87 and 88 and a factor of 0.5 for TCBT 
94. Assuming bioavailability factors similar to rats the accumulation factor would 
become 1.5, 0.5 and 0.03 for TCBT 87, 88 and 94 respectively. Based on the adipose 
tissue levels of the PCBs (Petreas et al., 2000) assuming that these levels were based 
on a daily intake of 89 ng/kg, the accumulation factor would range between 123 and 
1235. Thus, TCBTs accumulate marginally compared to the PCBs. 
The presented procedure to extrapolate in vitro metabolism to the in vivo situation 
for highly lipophilic substances like TCBTs provides reasonable estimates of the in 
vivo metabolism, under the assumption of rapid diffusional processes. Thus, this 
extrapolation procedure could be used to parameterise PB-PK models with respect to 
metabolism.
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CHAPTER 8 
GENERAL DISCUSSION  
 
 
 
 
 
 
 
 
In the early 1970s, the use of polychlorinated biphenyls (PCBs) was prohibited 
because of their persistence in the environment and the accumulation in higher 
trophic levels of the food chain. Exposure to PCBs may elicited a variety of toxic and 
biological effects (Safe, 1994). Due to the regulations concerning the use of the PCBs, 
alternatives were developed. Ugilec 141 is one of the replacements of the PCBs. This 
technical mixture consists of tetrachlorobenzyltoluenes (TCBTs) and has similar 
physicochemical properties as the PCBs. A few years after the commercial 
introduction of the TCBTs in Europe, this PCB substitute was also found in tissues 
of aquatic species, like fish, at levels that compared to that of PCBs (Fuerst et al., 
1987b; Leonards and DeVoogt, 1989; Wammes et al., 1997). Due to their 
physicochemical properties it was assumed that TCBTs could also accumulate in 
humans by consuming food contaminated with these substances and pose similar 
risks as PCBs. Hence, in 1994 similar regulations became effective in the European 
Union for TCBTs as for PCBs. These implied that in new machinery the use of 
Ugilec 141 was prohibited. However, from old devices the TCBTs could still leak into 
the environment and pose a possible health risk by accumulation in the food chain. 
The first objective of this thesis was to gain insight in the kinetics of TCBTs and 
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compare it with that of the PCBs, with special emphasis on possible food chain 
accumulation from fish to mammals, including humans. To achieve this, experiments 
were performed with three TCBTs and some PCBs that were tetra-, penta-, hexa- or 
hepta- chlorinated (PCB 52, 77, 80, 101, 118, 126, 136, 155, 180). Three TCBTs were 
selected out of the possible 96 isomers because of their supposed interaction with the 
Ah-receptor, which is a prerequisite to cause dioxin-like toxicity. The selected PCBs 
were closely related to the Ugilec 141 isomers with respect to the physicochemical 
properties, e.g. their lipid solubility as expressed by the octanol to water partition 
coefficient. Since metabolism was the rate-limiting step in the elimination of the 
PCBs, it was suggested that this would also be the case for the TCBTs. Thus, to 
determine possible accumulation of TCBTs and PCBs metabolic rate constants were 
determined in vitro using fish, rat, and human hepatic microsomes (Chapter 2, 3 and 
4). Furthermore, in vivo studies have been performed to determine the tissue 
distribution of the selected TCBTs and PCB 77, 101 and 118 (Chapter 5 and 6) after 
intravenous or oral exposure. With physiologically based pharmacokinetic (PB-PK) 
modelling the kinetics of these TCBTs and PCBs were quantitatively described. The 
information from the chapters 2, 3, 4, 5 and 6 was integrated in a PB-PK model to 
estimate the tissue disposition in humans (Chapter 7). 
The second goal was to identify the cytochrome P450 (CYP) enzymes involved in 
the metabolism of the selected TCBTs and PCBs (Chapter 3 and 4), to eventually 
indicate the possible contribution of extrahepatic tissue to the metabolism. 
One of the central themes in human toxicology is the validation of methods that 
are used to extrapolate experimental data obtained from experimental animals, or 
from in vitro studies to the human situation. In our study in vitro metabolic rate 
constants obtained from rat and human liver microsomes (Chapter 2, 3, and 4) were 
extrapolated to in vivo values for the use in a rat and human PB-PK model for TCBTs 
(Chapter 7). Thus, the third goal of this study was to evaluate the relationship 
between in vitro and in vivo values and the merit of these in vitro parameters in PB-PK 
modelling (Chapter 5).  
KINETICS OF TCBTS 
Absorption  
The presently observed high bioavailabilities of PCB 77, 101 and 118 in our 
study, ranging from 60 to 100% (Chapter 6), indicate their efficient absorption from 
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the GI-tract, which agrees with absorption efficiencies reported earlier (Fries et 
al., 1989; Tanabe et al., 1981). In general, the absorption efficiency of PCBs depends 
on lipid solubility and the molecular size (Tanabe et al., 1981). Although the 
bioavailability of the individual TCBTs was relatively low (between 6 and 48%), it was 
expected that the TCBTs, with comparable lipid solubility and molecular size, would 
be absorbed from the gut with comparable efficiencies as PCBs (Chapter 6). After the 
absorption, PCBs and other highly lipophilic substances e.g. DDT and dioxins 
sequester in chylomicrons in the lymph and are transported to the thoracic duct 
where lymph mixes with the venous blood (Busbee et al., 1985; Charman et al., 1997; 
VandenBerg et al., 1994). The PB-PK model for oral uptake including either transport 
via the lymphatic route, or via the portal vein route, did not provide statistical 
evidence to express preference for one of both models (Chapter 6). Possible 
transport via the lymphatic route has some kinetic implications that will be discussed 
in the metabolism section. 
Tissue distribution and disposition 
The tissue distribution of TCBTs and PCBs after a single bolus injection of a 
mixture of TCBTs and PCBs (Chapter 5 and 6) in rat showed comparable patterns 
and agree with literature data for PCBs, dioxins and other polyhalogenated 
hydrocarbons (Kedderis et al., 1993; Matthews and Dedrick, 1984; VandenBerg et al., 
1994). In the rat the adipose tissue is the main storage site followed by skin and 
muscle. After an initial distribution to the well-perfused liver the TCBTs redistribute 
to the skin, muscle, and adipose tissue (Chapter 5 and 6). In humans however, the 
PB-PK model simulations of the tissue concentrations after a single dose (Chapter 7) 
showed that initially the skin is the main storage compartment followed by the 
adipose tissue. This disparity, with respect to the tissue distribution in rats, is likely 
due to the larger adipose tissue depots (21 %) in humans compared to the rat (7 %). 
Since the fat volume is larger in humans the concentrations, after equal dosing, will be 
lower compared to the fat tissue of the rat. 
The tissue distribution of the TCBTs in rats illustrates that the lipophilicity of 
these chemicals is the major determinant for the tissue disposition. However, the 
isomer specific tissue distribution of the TCBTs indicates that other factors beside 
lipophilicity influence this process (Chapter 5). Most pronounced was the 7 fold 
higher liver to blood partition coefficient of TCBT 87 relative to that of the other 
two TCBTs. Such selective liver retention has been observed previously for 
polyhalogenated aromatic hydrocarbons like 2,3,7,8-TCDD or PCB 126. This 
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retention was due to binding to CYP1A2 in the liver, resulting in relatively high liver 
to blood partition coefficients (DeVito et al., 1998; VanBirgelen et al., 1994a). A planar 
structure appeared to be a prerequisite for this binding to CYP1A2 (DeVito et al., 
1998; VanBirgelen et al., 1994b). Theoretically, TCBT 87 and 88 were the most likely 
structures to adopt a planar conformation (VanHaelst, 1996), however, based on the 
enzymes that metabolise the TCBTs in rats and humans, it was suggested that these 
isomers most probably have a non-planar conformation (Chapter 3 and 4). Since 
neither TCBT 88 nor TCBT 94 elicited a preference for the liver, the conformation 
of TCBT 87 might thus explain the disparity in the liver to blood partitioning. Thus 
possibly the methyl-group in the ortho position might determine the selective retention 
by the liver.  
Metabolism 
Different species 
Metabolism of the TCBTs, similar to the PCBs, is considered to be the rate-
limiting step in the elimination of these compounds. Rat hepatic microsomes 
metabolised the TCBTs 2 to 50 times faster than the selected PCBs (Chapter 3), while 
human hepatic microsomes metabolised the TCBTs even 10 to 300 times faster than 
the selected PCBs (Chapter 4). Trout hepatic microsomes with their relatively low 
concentrations of biotransformation enzymes and the relative low metabolic activity 
compared to mammals (Sijm and Opperhuizen, 1989), metabolised neither the 
TCBTs (Chapter 2) nor the PCBs to a detectable rate within in the observed time-
span (Murk et al., 1994; White et al., 1997). Thus, these results imply that mammals 
eliminate TCBTs faster than PCBs, while in fish elimination was expected to be 
equally slow for both categories of compounds. Based on these results, we suggested 
that the body burden of TCBTs in fish would be comparable to the body burden of 
PCBs. This is substantiated by the finding of comparable tissue levels in the eel 
(Wammes et al., 1997). In mammals, however, due to the fast metabolism of the three 
TCBTs, the body burdens of these substances are suggested to be lower than for the 
PCBs. 
Role of Cytochrome P450 enzymes 
Various CYP enzymes appeared to metabolise the three TCBTs and some PCBs 
in both rat and human liver (Chapter 3 and 4). Table 1 summarises the main results.  
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Table 1. Overview of the major enzymes involved in the metabolism of the TCBTs and the PCBs 
using hepatic microsomes 
 Rat Human 
TCBT 87,88, 94 CYP2B1, 2B2, 3A1, 3A2 CYP2B6, 3A4 
PCB 52, 101, 136 CYP2B1, 2B2, 3A1, 3A2 CYP2B6, 3A4 
PCB 77 CYP1A1, 1A2 CYP1A2 
 
Isomer dependent metabolism was observed for the three TCBTs in Chapter 2, 3, 
and 4. TCBT 94 was metabolised faster than TCBT 88 and TCBT 87 in both rats and 
humans. Since the same CYPs are involved in the metabolism for all three isomers 
(Table 1) it is obvious that the substitution pattern of the molecules govern their rate 
of metabolism, affecting the affinity of the enzyme for the individual TCBTs. 
Furthermore, it was observed that, similar to the TCBTs, the more bulky PCBs 
were also metabolised by CYP2B, while the planar PCB 77 was metabolised by 
CYP1A1 and 1A2. In general, it appeared that more bulky molecules are preferably 
metabolised by CYP2B enzymes in both rat and humans (Lewis, 1997; Lewis et al., 
1999; Lewis and Lake, 1997), while planar PCBs and other planar molecules like 
polycyclic aromatic hydrocarbons e.g. benzo[a]pyrene were preferably metabolised by 
either CYP1A1 or CYP1A2 (Gonzalez and Gelboin, 1994; Zhang et al., 1997). Thus, 
the observation that the TCBTs were metabolised by CYP2B enzymes in stead of 
CYP1A2 suggests that the TCBTs adopt a reltively non-planar conformation. This 
could imply that the interaction with the Ah-receptor, which requires a planar 
conformation, is not likely. Thus the potency of these TCBTs to induce dioxin-like 
toxicity via this receptor is expected to be low.  
Extrahepatic metabolism and first-pass metabolism 
Strong correlations were observed between metabolism of the three TCBTs and 
the examined ortho-substituted PCBs and CYP2B enzyme activities, and weaker 
correlations with CYP3A enzyme activities in both human and rat liver microsomes 
(Chapter 3 and 4). CYP2B and CYP3A in the rat are the major enzymes, with CYP3A 
occurring in the highest concentrations. In humans however, CYP2B6 is only a minor 
hepatic enzyme (0.2 % of the total CYP concentration) (Shimada et al., 1994), while 
CYP3A4 is a major hepatic enzyme (30-40 % of the total CYP concentration) (De 
Wildt et al., 1999; Gonzalez, 1992). This implies that although the concentration of 
CYP2B6 enzyme is low, the metabolism might be efficient. Consequently, the weaker 
affinity of CYP3A for the chlorinated compounds results in less efficient metabolism.  
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CYP identification was performed by correlation analysis and the use of selective 
inhibitors (Chapter 3 and 4), to elucidate whether extrahepatic tissue could contribute 
to the metabolism of the three TCBTs and the selected PCBs. CYP2B and CYP3A 
are the most important enzymes in the intestines and the lung of the rat (De Waziers 
et al., 1990). In humans the relative amounts of CYP3A4 and CYP2B6 expressed in 
the intestines are comparable to that in the liver; CYP3A4 occurs in high 
concentrations (30-40 % of the total CYP concentration) (De Waziers et al., 1990; De 
Wildt et al., 1999; Gervot et al., 1999; Zhang et al., 1999) and the CYP2B6 
concentrations are low (Gervot et al., 1999). Thus after oral uptake first-pass 
metabolism in the intestines could occur, reducing the oral bioavailability of the 
TCBTs and the ortho-substituted PCBs in both rat and humans. In Chapter 6 this has 
indirectly been demonstrated for the three TCBTs in the rat. The oral bioavailability 
of these TCBTs in rat was 6, 20 and 48 % for TCBT 94, 88, and 87, respectively. 
The contribution of the intestines to the first-pass metabolism could be 
anticipated because the compounds entered the organism via the GI-tract (Chapter 
6). The contribution of the lungs is less obvious. The lungs could contribute to the 
first-pass metabolism in the case that the TCBTs are transported via the lymphatic 
route. After the lymph has mixed with the venous blood, the venous blood with the 
TCBTs is pumped to the lungs first, before reaching the systemic circulation. Rat 
lungs have a 1.5 times higher expression of CYP2B than the rat liver (De Waziers et 
al., 1990), which could imply presystemic metabolism, i.e. first-pass, of the TCBTs in 
the lungs resulting in a reduced tissue concentrations. Chapter 6 was not conclusive 
about uptake either via the lymphatic route or via the portal vein route. However, in 
general many highly lipophilic substances are transported via the lymphatic system to 
the systemic circulation (Charman et al., 1997). Thus, transport via the lymph of these 
highly lipophilic TCBTs and PCBs cannot be excluded. This implies that the lungs 
could play an important role in the first-pass metabolism of the studied compounds 
but also during the passage of systemic blood through the lungs.  
The toxicity of TCBTs has been investigated sparsely while that of TCBT 
metabolites has not been subject of a research programme. With respect to PCBs, 
hydroxylated PCBs have been associated with inhibition of vitamin A and thyroxin 
transport, and with estrogenic effects (Brouwer and VandenBerg, 1986; Kramer et al., 
1997; Morse et al., 1996). Thus, the lower bioavailability of the TCBTs by intestinal 
first-pass elimination, does not necessarily imply a reduction of the toxic risk.  
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Elimination 
In the rat, terminal half-lives of the TCBTs in the blood, were comparable to 
those of PCB 77, 101 and 118, ranging from 3 to 4 days, while the in vitro metabolic 
rate constants of the TCBTs were 2 to 50 times faster relative to the PCBs. In 
humans the elimination of the TCBTs was slower, as indicated by their estimated 
long terminal half-lives, ranging from 22 to 111 days (Chapter 5, 6, and 7).  
Figure 1 illustrates the effect of metabolic rate constants on the terminal half-lives 
in the rat using the PB-PK model (Chapter 5). The terminal blood half-life is sensitive 
to changes in the metabolic rate constants when metabolism is relatively slow 
(Kmet<1). Increasing Kmet does not affect the terminal half life substantially, 
indicating that metabolism is not the only factor determining the half-life of the 
TCBTs. It appeared from the sensitivity analysis in chapter 5, that the perfusion rate 
of the adipose tissue and the liver play a significant role in the amount that was 
metabolised.  
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Figure 1. The effect of metabolic rate constants on the terminal half-life of TCBTs from the rat 
blood using the PB-PK model (Chapter 5) 
Food chain accumulation 
The kinetic studies with the TCBTs were performed to assess if TCBTs would 
accumulate throughout the food chain like PCBs. The major factor determining the 
differences in the toxicokinetics between the selected TCBTs and PCBs in mammals 
were the differences in metabolic rate constants. Since in fish, the metabolic rate 
constants of the TCBTs and the PCBs were slow and therefore hardly detectable 
(Chapter 2), it was assumed that the absorption, tissue distribution and elimination 
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would be analogous for both types of compounds like in mammals. This explains that 
the levels of the TCBTs and PCBs in fish lie in the same order of magnitude (Fuerst 
et al., 1987b; Leonards and DeVoogt, 1989; Wammes et al., 1997).  
Due to the low oral bioavailability of the TCBTs in the rat, the tissue levels would 
be 52 to 95 % lower than for the PCBs at equal exposure levels. Similar low oral 
bioavailabilities were suggested for humans because of the presence of CYP2B6 and 
3A4 in the human gut tissue. Furthermore, once absorbed the TCBTs are 
metabolised 2 to 50 times faster in the rat and 10 to 300 times faster in humans than 
the PCBs in the human liver. Based on our study we must conclude that food chain 
accumulation of TCBT to levels similar to PCBs is not likely to occur. This was 
confirmed by model simulation using a PB-PK model for humans (Chapter 7). The 
simulated tissue levels of TCBTs under steady state conditions were 100 to 1000 folds 
lower compared to measured human tissue levels of total PCBs and relatively low 
bioaccumulation factors (BAF) were calculated (eq. 1) 
DoseF
CffactorationBioaccumul ss
*
=    eq. 1 
where Cf ss (µg/kg ) is the steady state concentration in the adipose tissue of the 
TCBT or PCB and F is oral bioavailability and Dose is the daily dose in µg/kg. 
For the TCBTs in humans BAF based on the estimated tissue levels, ranged from 
0.03 to1.5, while for PCBs it ranged from 100 to 1000 using adipose tissue levels as 
reported in the literature. These calculations were also performed for TCBTs and 
PCBs in the rat. The BAF in the adipose tissue relative to the daily intake of 89 
ng/kg/day was 4.8, 3.8 and 2.8 for TCBT 87, 88 and 94 respectively, while for PCB 
77, 101 and 118 this was 9.2, 9.3 and 232, respectively. Thus, the accumulative 
potential of the TCBTs is a factor 2 to 100 lower than for the PCBs in the rat. 
PB-PK MODELLING 
The toxicokinetics were analysed with PB-PK models that were parameterised 
using physiology data from literature and in vivo tissue concentration data to derive 
partition coefficients (Chapter 5 and 6). The in vivo metabolic rate constants as well as 
the diffusional clearance constants were obtained by optimising the PB-PK model of 
the rat to the tissue concentration data.  
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This model was then scaled to the human situation (Chapter 7) to estimate the 
kinetics of TCBTs in humans. This scaling is associated with uncertainties with 
respect to the in vitro-in vivo extrapolation of human metabolism, and the interspecies 
extrapolation of the diffusional clearance constant. In the following paragraphs these 
uncertainties are being discussed.  
In vitro-in vivo extrapolation  
In vitro metabolic rate constants from the hepatic microsomes represent the 
metabolism in a subcellular fraction of the liver. Often these values can be 
extrapolated accurately to estimate metabolism in vivo (Carlile et al., 1997; Hayes et al., 
1995; Houston, 1994b; Houston and Carlile, 1997). However, repeatedly, the 
estimates of the in vitro studies underestimate the in vivo metabolism (Obach, 1996). 
This was also demonstrated in chapter 5 for the three TCBTs. Insertion of the in vitro 
metabolic rate constant in the PB-PK model, underestimated the elimination from 
the rats with a factor 3 to 10.  
In general, in vitro metabolic rates are obtained by incubating the substrate at a 
single concentration of microsomal protein in the incubation fluid. Chapter 7 
illustrates that the metabolic rate constants are dependent on the amount of 
microsomal protein in the incubation fluid. Increasing the protein concentration 
increases the metabolic rate constant non-linearly. Since in the whole liver the 
concentration of the microsomal fraction is lower (0.045 mg/ml) than the commonly 
used 1 mg protein per ml, this suggests that extrapolation of one single in vitro 
metabolic rate constant would result in a good estimate of the in vivo metabolism by 
coincidence. This non-linear behaviour of the in vitro metabolism was explained by 
the free fraction of the substrate in the microsomes and in the incubation fluid as well 
as their respective volumes (VanEijkeren, 2000). Taking these factors into account 
provides estimates of the specific intrinsic clearance and the free fraction in the 
microsomes. Since the liver cells contain these microsomes exist as membrane bound 
enzymes in the hepatocyte, it is assumed that these parameter values are the same in 
the whole liver. However, partitioning in the whole liver is likely to deviate from that 
in the microsomes e.g. the lipid fraction is higher in the whole liver than in the 
microsomes in which more of the substrate could be dissolved, reducing the free 
fraction of the substrate. Now, the question arises whether the fraction that dissolves 
in the lipid fraction should be considered as bound or as still available for 
metabolism. This could be explored by increasing the lipid fraction in the incubation 
fluid and determining the effect on the metabolic rates.  
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The difference between the in vitro and in vivo estimates of the metabolism was 
suggested to be partly due to metabolism in the extrahepatic tissue. Especially the 
lungs could contribute significantly to the metabolism in the rat, as discussed 
previously, because of their high content of CYP2B relative to the liver (De Waziers 
et al., 1990) which is one of the major enzymes metabolising the TCBTs (Chapter 3). 
In addition, hundred percent of the cardiac output flows through the lungs, while 
only 25 % of cardiac output perfuses the liver (Brown et al., 1994). Thus, the lungs 
could metabolise significant amounts of the TCBTs. It is suggested that the in vitro-in 
vivo extrapolation would improve taking metabolism in this tissue into account. It 
appeared that the contribution of the intestines to the total metabolism after 
intravenous injection of the drug midazolam, which is metabolised by CYP3A in 
humans, was only 8%, while after oral administration this was 43%. This indicates 
that once in the systemic circulation the contribution of the intestines to the 
metabolism of midazolam becomes less important (Hall et al., 1999). This suggests for 
the TCBTs that the contribution of the intestines to the metabolism has already been 
taken into account in the factor for the oral bioavailability which is low because of 
first-pass metabolism in the gut wall (Chapter 6). Thus, the lungs are one of the most 
likely organs that might explain the observed difference between in vitro and in vivo 
metabolic rate constants.  
Diffusional clearance 
The PB-PK model for TCBTs and PCBs in the rat includes a diffusional 
clearance constant to correct for the delay in tissue uptake by the adipose tissue, 
muscle and skin (Chapter 5 and 6). The metabolic rate constants and the diffusional 
clearance constants were obtained by optimising the PB-PK model to the tissue 
concentration data in rats. This PB-PK model was extrapolated to the human 
situation (Chapter 7). The diffusional clearance constants for the adipose tissue, skin, 
and muscle were inserted in the human model assuming that the uptake process in 
human tissue would be equal to that in rats. To assess the validity of this interspecies 
extrapolation, physiological insight in this constant is needed. Two possible uptake 
mechanisms are proposed here, that possibly provide a physiological interpretation of 
the diffusional clearance constant.  
The diffusion limited uptake could be explained by the volume of the cells and 
the slower rate of perfusion. The tissue next to the artery or arteriole is in equilibrium 
with the blood, but deeper in the tissue this equilibrium does not exist yet, i.e. a large 
volume does not contain the compound. The diffusion of the compound from the 
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cell membrane to the centre is considered rate limiting (Lutz et al., 1980). Thus, 
analysing the tissue when not all the tissue is in equilibrium with the blood will result 
in a lower tissue concentration. In the model the diffusional clearance constant is 
used to correct for this delayed uptake. However, determinants influencing this factor 
have not been studied. Assuming the diffusion limitation is explained by the volumes, 
then the diffusional clearance is expected to depend on the tissue it self, and not on 
the isomers. However, optimised parameter values of this constant for the TCBTs 
appear to depend on the isomer, while that of the PCBs appear to independent of the 
congener but dependent on the tissue. 
The delayed uptake in these tissues could also be due to an active process that is 
rate limiting the uptake. It has been observed that lipoproteins, including 
chylomicrons, low densitiy lipoprotein (LDL), high density lipoprotein (HDL) and 
very low density lipoprotein (VLDL) play an important role in the transport of PCBs 
(Busbee et al., 1985; Mohammed et al., 1990; Noren et al., 1999; Spindler Vomachka et 
al., 1984). The PCBs equilibrate instantaneously between the lipoprotein fractions 
(Maliwal and Guthrie, 1982; Mohammed et al., 1990) suggesting that the interactions 
are non-specific between the different lipoprotein fractions. The distribution of the 
PCBs depends solely on the concentrations of the different lipoprotein fractions 
(Matthews et al., 1984). After absorption from the GI-tract the PCBs are transported 
via chylomicrons to the liver where they are processed (Borlakoglu et al., 1990b; 
Busbee et al., 1985). 
Apart from the liver, the adipose tissue and the muscle contain receptors for the 
uptake of processed lipoproteins, including chylomicron remnants (Cooper, 1992), 
These receptors are known as lipoprotein lipases (LPL) and are both receptor and 
enzyme. LPL degrades the triglycerides to take up the free fatty acids. It is now 
hypothesised that the lipophilic chemicals are released because of the degradation of 
the lipoprotein, followed by tissue uptake. This process is assumed to be affected by 
the number of these receptors in the tissues.  
The lipophilic vitamin A is dissolved in the lipoproteins and the chylomicron 
remnants that are recognised by the LPL receptor on the adipose tissue and the 
muscle. In mice overexpressing LPL resulted in higher tissue concentration of 
vitamin A, relative to mice with normal LPL expression (VanBennekum et al., 1999). 
In addition, the adipose tissue and the muscle can take up whole lipoproteins (Karpe 
et al., 1997). This suggests that PCBs or TCBTs could be taken up accordingly. This 
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receptor-mediated uptake via LPL has also been suggested by Borlakoglu et al. 
(1990b), however, data to support this hypothesis are still lacking. The skin also 
demonstrated a delayed uptake, but it does not have the lipoprotein receptors. 
However, the skin contains large adipose tissue depots subcutaneously, where the 
PCBs could be stored according to the process as described above. Thus it is 
hypothesised that the diffusional clearance constant depends on the number of LPL. 
Human PB-PK model 
The aim of this thesis was to compare the kinetics of three TCBTs with that of 
three PCBs in a quantitative way using PB-PK modelling and to estimate the possible 
accumulation of these compounds in humans. 
The PB-PK models of these TCBTs and PCBs in the rat described the kinetics of 
both categories of compounds adequately (Chapter 5 and 6). The advantage of these 
models is that they can be extrapolated to other species by scaling the physiological 
parameters, biochemical and physicochemical parameters (Chapter 7), which entail 
the above-discussed uncertainties. Despite these uncertainties all information about 
the toxicokinetics of the TCBTs so far, including metabolism, bioavailability, and 
tissue to blood partitioning, have been integrated in the PB-PK model resulting in 
substantiated estimates of tissue concentrations in the male human. These estimates 
of the TCBTs were approximately 100 to 1000 fold lower (Chapter 7) than the PCBs 
levels, indicating the much lower potential of the TCBTs to accumulate in human 
tissue. Thus, the PB-PK model provided insight in the human kinetics of the highly 
lipophilic substances. 
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CONCLUSIONS 
• Food chain accumulation of the TCBTs in mammals is up to two orders of 
magnitude lower in the rat and between two to three orders of magnitude lower 
in humans relative to the selected PCBs because of the faster metabolism of the 
TCBTs relative to the PCBs. In fish with their lower metabolic capacity 
accumulation of TCBTs occurs. 
• The oral bioavailability of the TCBTs is lower than that of PCB 77, 101 and 118, 
which is due to high first-pass elimination of the TCBTs that most likely occurs 
in the small intestines rather than in the liver.  
• CYP2B and CYP3A play an important role in the metabolism of the selected 
TCBTs and the non-planar PCBs, while the planar PCBs are metabolised by 
CYP1A enzymes. These enzymes are significantly expressed in the liver, the small 
intestines and the lungs. Thus these tissues can also contribute to the overall 
elimination of the TCBTs and the PCBs.  
• In vitro metabolic rates of the TCBTs were only a factor 2 to 3 lower compared to 
the in vivo metabolic rates, indicating their use for parameterisation of PB-PK 
models. 
• The in vivo kinetics of the three TCBTs equals that of the selected PCBs with 
respect to tissue distribution and disposition and, are evenly well described by the 
same PB-PK model representation. The individual parameter values reflected the 
compound specific properties. 
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APPENDIX A 
Mass balance differential equations 
For adipose tissue, skin and muscle the amount in the tissue (Ax) and tissue blood (Axb) are 
described by the following differential equations where CA denotes the blood concentration, Qx, 
Cvx, PAx, Cx and Px denote the blood flow, venous blood concentration, diffusional clearance, and 
tissue: blood partition coefficient, respectively, associated with tissue x: 
)(
Px
CxCvxPAx
dt
dAx
−=  eq.1 
)()( Cvx
Px
CxPAxCvxCAQx
dt
dAxb
−+−=  eq.2 
The amount in kidney and remaining tissue are described as follows: 
)(
Px
CxCAQx
dt
dAx
−=  eq.3 
Concentrations in these tissues are represented by the amount divided by the tissue volume: 
Vx
AxCx =  eq.4 
Metabolism is described as a first-order process, which occurs in the liver. The liver 
compartment is therefore described as: 
AlKmet
Pl
ClCAQl
dt
dAl *)( −−=  eq.5 
where Kmet represents the metabolic rate constant. 
 
PAxCQxPAx *=  eq. 6 
Where Qx is the blood flow through tissue x and PAxC is a constant representing part of the 
diffusional clearance (PAx) 
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SAMENVATTING 
Technische mengsels van vetoplosbare polychloorbifenylen (PCBs) zijn gebruikt 
als vloeistof in transformatoren, condensatoren en als brandvertragers, vanwege hun 
thermostabiliteit, chemische stabiliteit en hun goede geleidbaarheid. Door vuilstort, 
lekkage uit industriële toepassingen en ongelukken zijn PCBs in het milieu terecht 
gekomen, waar ze persisteren door hun chemische stabiliteit. Vanwege het 
vetoplosbare karakter van de verbindingen kunnen de PCBs accumuleren in de 
voedselketen. Dit wil zeggen hoe hoger in de voedselketen, hoe hoger de 
geaccumuleerde concentratie.  
PCBs blijken in diverse diersoorten toxische effecten te veroorzaken, zoals acute 
sterfte, leververgroting, verlies van lichaamsgewicht, atrofie van de thymus, 
onderdrukking van het immuunsysteem, reproductie- en ontwikkelingseffecten. De 
chemische stabiliteit, de accumulatie en de toxiciteit van de PCBs hebben ertoe geleid 
dat het gebruik ervan, mondiaal is verboden. Dit verbod leidde er vervolgens toe dat 
alternatieven werden ontwikkeld.  
Ugilec 141 is een van die alternatieven. Dit technische mengsel bestaat uit 
tetrachlorobenzyltoluenen (TCBTs). Deze isomeren hebben vergelijkbare fysisch-
chemische eigenschappen als PCBs. Dit deed vermoeden dat de TCBTs ook 
vergelijkbare problemen als PCBs zouden kunnen opleveren wat betreft persistentie 
in het milieu, en accumulatie in de voedselketen. Enkele toxiciteitstudies toonden aan 
dat de toxische effecten van TCBTs overeenkwam met die van PCBs, maar dat de 
effecten pas optraden bij hoger concentraties. Vanwege de verwachte problemen is in 
1994 door de Europese Unie ook het gebruik van TCBTs in nieuwe apparatuur 
verboden. 
In dit proefschrift is onderzocht of TCBTs in de voedselketen kunnen 
accumuleren en met name of de mens een risico loopt dit soort verbindingen te 
kunnen ophopen. Om deze vraag op te helderen is inzicht in de toxicokinetiek nodig. 
Dit houdt in alle processen die te maken hebben met opname van stoffen in het 
lichaam, verdeling van de stof over de verschillende weefsels en organen, afbraak van 
de stof (=metabolisme), en de uitscheiding. De kinetische processen kunnen 
gemodelleerd worden met behulp van op de fysiologie gebaseerde farmacokinetische 
modellen (PB-PK modellen). Deze modellen integreren fysiologische gegevens zoals 
bv. bloedstroomsnelheid, weefselvolume, en orgaangrootte, fysisch-chemische 
eigenschappen van de desbetreffende stof zoals bv. vetoplosbaarheid en 
  110 
biochemische eigenschappen zoals bv. metabolisme snelheid. Het voordeel van dit 
soort PB-PK modellen is dat modellen die bijvoorbeeld voor de rat zijn ontwikkeld, 
vertaald kunnen worden naar de mens door fysiologische gegevens aan te passen aan 
die van de mens. Voor de ontwikkeling van dit soort modellen wordt vaak gebruik 
gemaakt van in vitro methoden om metabolisme snelheden te bepalen. Een van de 
moeilijkheden door het gebruik van in vitro methoden is dat de resultaten vertaald 
moeten worden naar in vivo waarden. Die extrapolatie brengt vaak een aantal 
onzekerheden met zich mee.  
Van PCBs is bekend dat metabolisme de snelheidsbepalende stap is in de 
eliminatie van deze verbindingen. Dit betekent dat eenmaal gemetaboliseerd de PCBs 
snel het lichaam verlaten. Aangezien TCBTs lijken op PCBs is verondersteld dat dit 
ook voor hen geldt. Door te meten hoe snel de TCBT ten opzichte van de PCBs 
worden afgebroken kan een inschatting gemaakt worden of TCBTs meer of minder 
zullen accumuleren dan PCBs. Daarnaast, door de afbraaksnelheid te meten in 
verschillende diersoorten, kan tevens een indruk verkregen worden van de verschillen 
in accumulatie tussen diersoorten. 
Dioxine en PCBs met een platte structuur kunnen interacties aangaan met de 
arylhydrocarbon (Ah) receptor, wat ten grondslag ligt aan hun specifieke toxiciteit. 
Om een interactie met de Ah-receptor aan te gaan is de grootte en de ruimtelijk 
structuur van het molecuul van belang. Moleculen met een platte (=planaire) 
conformatie zoals dioxines en planaire PCBs passen op die receptor. Ugilec 141 
bestaat uit 69 isomeren. Hiervan zijn slechts drie onderzocht (nr. TCBT 87, 88 en 94), 
omdat theoretisch gezien deze drie isomeren een planaire conformatie kunnen 
aannemen en daardoor mogelijke een interactie kunnen aangaan met de Ah-receptor. 
Op basis hiervan zouden deze drie isomeren toxicologisch het meest relevant zijn. 
In hoofdstuk twee is een methode beschreven waarmee de eerste en langzaamste 
stap in het metabolisme wordt gemeten. Die eerste stap is een hydroxylatie die door 
cytochrome P450 enzymen (CYP) wordt gekatalyseerd. Cytochrome P450 is een 
enzym systeem dat bestaat uit veel iso-enzymen. Die enzymen bevinden zich in zeer 
hoge concentratie in de lever en in lagere concentraties in andere organen en weefsels. 
De enzymen kunnen geïsoleerd worden door de lever fijn te malen en te 
centrifugeren. Het product dat uiteindelijk overblijft heet microsomen. Met deze 
microsomen van de ratte- en visselever zijn experimenten uitgevoerd om de 
afbraaksnelheid van de drie TCBTs te bepalen. De rattelever bleek de drie TCBTs 
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sneller af te breken dan de visselever. Ook bleken de CYPs met een verschillende 
snelheid de TCBTs af te breken: TCBT 94 >>TCBT 88>TCBT 87. 
In hoofdstuk drie en vier is, met de methode uit hoofdstuk twee, de metabole 
afbraaksnelheid van de drie TCBTs en enkele PCBs bepaald in de lever van de rat en 
de mens. Bovendien is in die hoofdstukken ook beschreven welke CYPs de afbraak 
van die verbindingen bewerkstelligen. Uit beide hoofdstukken bleek dat zowel de 
levers van de mens en de rat TCBTs sneller afbreken dan PCBs. De gemiddelde 
afbraaksnelheid van TCBTs door de mens was vergelijkbaar met die van de rat. Deze 
resultaten zouden kunnen betekenen dat PCBs makkelijker accumuleren dan TCBTs 
in beide zoogdieren. De volgende iso-enzymen bleken betrokken te zijn bij de afbraak 
van de drie TCBTs (nr. 87, 88, 94) in de rat: CYP2B1, CYP2B2, CYP3A1,CYP3A2. 
In de mens waren dat de gerelateerde enzymen: CYP2B6 en CYP3A4. De PCB met 
een platte structuur (PCB 77) werd afgebroken door CYP1A1 en CYP1A2 in zowel 
de rat als de mens. De bolvormige PCBs (nr. 52, 101, 136) werden afgebroken door 
dezelfde enzymen als de TCBTs. Hieruit is geconcludeerd dat de TCBTs mogelijk 
bolvormig zijn, waardoor interactie met de Ah-receptor niet waarschijnlijk is. Dit 
impliceert dat ervan TCBTs geen dioxine-achtige toxiciteit te verwachten is.  
In hoofdstuk 5 is de ontwikkeling van een PB-PK model voor TCBTs in de rat 
beschreven. Bovendien is in dit hoofdstuk een vergelijking gemaakt tussen de in vitro 
metabole afbraaksnelheid en de geschatte in vivo metabole afbraaksnelheid. Ratten zijn 
eenmalig intraveneus gedoseerd met een mengsel van de drie TCBTs. Op 
verschillende tijdstippen is gemeten in bloed, lever, spier, vet en de nier hoe hoog de 
concentratie van de TCBTs was. De fysiologische gegevens voor het model waren 
afkomstig uit de literatuur, de weefselverdeling van de TCBTs werd berekend uit de 
beschikbare weefsel-concentratie data. De waardes voor metabole afbraaksnelheid en 
de diffusiesnelheid van bloed naar huid, vet en spier werden geschat met behulp van 
het PB-PK model, door parameter waardes zo te variëren dat de modelvoorspelling 
zo goed mogelijk de geobserveerde data voorspelt. De voorspelde in vivo metabole 
afbraaksnelheid bleek slechts twee tot drie maal hoger te zijn dan de in vitro gemeten 
metabole afbraaksnelheid. Hieruit werd geconcludeerd dat de in vitro methode 
waardevolle gegevens opleverde voor het gebruik in PB-PK modellen. 
In het algemeen worden PCBs en TCBTs via voedsel opgenomen. Die orale 
route kan de hoeveelheid van de verbindingen die het bloed bereikt 
(=biobeschikbaarheid) beïnvloeden. In hoofdstuk zes is de biobeschikbaarheid van 
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de drie TCBTs en enkele PCBs bepaald. Ratten kregen een mengsel van TCBTs en 
PCBs toegediend op een korrel voer. Op verschillende tijdstippen na consumptie is 
de concentratie van de TCBTs en de PCBs bepaald in bloed en weefsels. Bovendien 
is een mengsel van PCBs intraveneus toegediend. Met behulp van het PB-PK model 
uit hoofdstuk vijf en met een nieuw PB-PK model voor de PCBs na intraveneuze 
toediening, zijn de resultaten van de orale studie beschreven. Hiervoor is alleen de 
biobeschikbaarheid als parameter ingevoerd. De biobeschikbaarheid van TCBT 94 
was 5%, TCBT 88 was 20% en TCBT 87 was 48% ten opzichte van de intraveneuze 
toediening. Voor de PCB 77, 101 en 118 was de biobeschikbaarheid respectievelijk: 
60, 75, en 100%. De relatief lage biobeschikbaarheid van de TCBTs kon verklaard 
worden door afbraak van de verbindingen in het maagdarmkanaal, die relatief hoge 
concentraties bevatten van de enzymen die betrokken zijn bij de afbraak van de 
TCBTs. 
In hoofdstuk zeven is een PB-PK model beschreven voor de kinetiek van TCBTs 
in de mens, wat de resultaten uit de bovenstaande hoofdstukken integreert. In 
hoofsdtuk vijf werd reeds aangetoond dat de in vitro metabole afbraaksnelheid goede 
resultaten opleverde om in vivo metabolisme te voorspellen in de rat. In hoofdstuk 
zeven is deze in vitro-in vivo extrapolatie nader onderzocht. Het PB-PK model voor de 
mens is gebruikt om weefselconcentraties te voorspellen na een eenmalige dosering 
en na 300 dagelijkse doseringen. Omdat er geen gegevens waren over 
weefselconcentraties van TCBTs in de dagelijkse voeding van de mens is een 
gemiddelde dagelijkse inname van PCBs gebruikt. De resulterende 
modelvoorspellingen zijn vergeleken met weefselconcentraties van PCBs die gemeten 
zijn in de mens. Er bleek dat de mens TCBTs 2 tot 100 keer minder accumuleert 
vergeleken met PCBs. Dit verschil kon o.a. verklaard worden door verschil in 
metabole afbraaksnelheid tussen TCBTs en PCBs 
Uit de resultaten die beschreven zijn in dit proefschrift blijkt dat de lever 
microsomen van de forel niet in staat zijn de drie TCBTs meetbaar te metaboliseren, 
terwijl lever microsomen van de rat en de mens hiertoe wel instaat zijn. Hieruit is 
geconcludeerd dat vissen TCBTs wel accumuleren, maar dat zoogdieren, zoals 
bijvoorbeeld de mens, dit veel minder doen.  
Bovendien is gebleken dat TCBTs sneller worden afgebroken dan PCBs door 
zowel de rat als de mens door met name CYP2B en CYP3A. Deze enzymen komen 
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tevens voor in andere weefsels dan in de lever, zoals de darm. Dit verklaart de geringe 
biobeschikbaarheid van TCBTs.  
Door de snellere afbraak van TCBTs ten opzichte van PCBs en de geringe 
biobeschikbaarheid, zullen TCBTs slechts in geringe mate accumuleren bij een 
continue blootstelling. Tevens kan afgeleid worden uit de enzymen die betrokken zijn 
bij de afbraak van de TCBTs, dat Ah-receptor gemedieerde toxiciteit van TCBTs niet 
waarschijnlijk is. Daarmee zijn voor zoogdieren, inclusief de mens, de risico’s, die 
verbonden zijn aan blootstelling aan TCBTs, te verwaarlozen. Dit in tegenstelling tot 
de aquatische organismen zoals vissen, die door trage afbraak TCBTs wel kunnen 
accumuleren. 
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